{"content":"<li class=\"n-box-item date-title\" data-end=\"1526702399\" data-start=\"1526616000\" data-txt=\"Monday, December 23, 2019\">Friday, May 18, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3358087\" data-ts=\"1526684001\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EVHC\" target=\"_blank\">EVHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3358087-reuters-hca-kkr-teaming-on-envision-buyout-bid-evhcplus-7_8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reuters: HCA, KKR teaming on Envision buyout bid; EVHC +7.8%</a></h4><ul>   <li>Envision Healthcare (NYSE:<a href='https://seekingalpha.com/symbol/EVHC' title='Envision Healthcare Holdings'>EVHC</a>) has <font color='green'>jumped 7.8%</font> after hours as Reuters reports HCA Healthcare (NYSE:<a href='https://seekingalpha.com/symbol/HCA' title='HCA Holdings, Inc.'>HCA</a>) and <a href='https://seekingalpha.com/symbol/KKR' title='KKR'>KKR</a> are <a href=\"https://www.reuters.com/article/us-envision-hlthcr-m-a-hca-healthcare-kk/exclusive-hca-kkr-team-up-for-envision-bid-sources-idUSKCN1IJ2UK\" target=\"_blank\">teaming up for a buyout bid</a>.</li>    <li>That team-up should give the two an edge over other buyout firms eyeing Envision, including a consortium of Carlyle Group (NASDAQ:<a href='https://seekingalpha.com/symbol/CG' title='The Carlyle Group'>CG</a>) and TPG Global, according to the report.</li>    <li>HCA has its eyes on Envision's AmSurg ambulatory surgery unit, with KKR planning to take over the rest.</li>    <li>Envision sold off its AMR ambulance unit to Air Medical last year for $2.4B. It had merged with AmSurg the year before that in an all-stock deal that would be undone by this bid.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3358087\" data-linked=\"Reuters: HCA, KKR teaming on Envision buyout bid; EVHC +7.8%\" data-tweet=\"$EVHC $EVHC $HCA - Reuters: HCA, KKR teaming on Envision buyout bid; EVHC +7.8% https://seekingalpha.com/news/3358087-reuters-hca-kkr-teaming-on-envision-buyout-bid-evhcplus-7_8?source=tweet\" data-url=\"https://seekingalpha.com/news/3358087-reuters-hca-kkr-teaming-on-envision-buyout-bid-evhcplus-7_8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3358083\" data-ts=\"1526679614\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HGSH\" target=\"_blank\">HGSH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3358083-china-hgs-real-estate-spikes-in-closing-minutes-to-30-gain\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">China HGS Real Estate spikes in closing minutes to 30% gain</a></h4><ul>   <li>China HGS Real Estate (NASDAQ:<a href='https://seekingalpha.com/symbol/HGSH' title='China HGS Real Estate, Inc.'>HGSH</a>) ended the day as one of Nasdaq's top gainers with a spike in the last 10 minutes of trading.</li>    <li>On heavy volume, shares jumped to a <font color='green'>30.2% gain</font> on no obvious news.</li>    <li>Volume ran more than 17 times normal for the thinly traded stock.</li>    <li>Shares are now <font color='red'>off 6.2%</font> in postmarket trade.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3358083\" data-linked=\"China HGS Real Estate spikes in closing minutes to 30% gain\" data-tweet=\"$HGSH - China HGS Real Estate spikes in closing minutes to 30% gain https://seekingalpha.com/news/3358083-china-hgs-real-estate-spikes-in-closing-minutes-to-30-gain?source=tweet\" data-url=\"https://seekingalpha.com/news/3358083-china-hgs-real-estate-spikes-in-closing-minutes-to-30-gain\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3358082\" data-ts=\"1526679441\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OEC\" target=\"_blank\">OEC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3358082-after-hours-gainers-losers-05-18-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers (05/18/2018)</a></h4><ul>     <li><b>Top gainers:</b>&nbsp;<a href='https://seekingalpha.com/symbol/OEC' title='Orion Engineered Carbons'>OEC</a>&nbsp;<font color='green'>+3.4%</font>.&nbsp;<a href='https://seekingalpha.com/symbol/JOBS' title='51job, Inc.'>JOBS</a> <font color='green'>+1.4%</font>.</li>     <li><strong>Top Losers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/EGY' title='VAALCO Energy, Inc.'>EGY</a> <font color='red'>-1.9%</font>. <a href='https://seekingalpha.com/symbol/MX' title='MagnaChip Semiconductor Corporation'>MX</a>&nbsp;<font color='red'>-1.4%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3358082\" data-linked=\"After Hours Gainers / Losers (05/18/2018)\" data-tweet=\"$OEC $OEC $JOBS - After Hours Gainers / Losers (05/18/2018) https://seekingalpha.com/news/3358082-after-hours-gainers-losers-05-18-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3358082-after-hours-gainers-losers-05-18-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:37 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3358039\" data-ts=\"1526671411\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GTXI\" target=\"_blank\">GTXI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3358039-gtxs-enobosarm-continues-to-demonstrate-treatment-effect-in-mid-stage-sui-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GTx&#39;s enobosarm continues to demonstrate treatment effect in mid-stage SUI study</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/17168387-gtx-updates-phase-2-enobosarm-clinical-trial-results-stress-urinary-incontinence-2018-aua\" target=\"_blank\">Updated results</a> from a Phase 2 proof-of-concept clinical trial evaluating GTx's (<a href='https://seekingalpha.com/symbol/GTXI' title='GTx, Inc.'>GTXI</a> <font color='green'>+1.4%</font>) enobosarm in postmenopausal women with stress urinary incontinence &#40;SUI&#41; continued to show a treatment benefit. The data were presented at the American Urological Association Annual Meeting in San Francisco.</li><li>All 18 women who completed the 12-week treatment period experienced clinically meaningful reductions (at least 50%) in SUI episodes per day (the primary endpoint). Mean stress leaks declined 81% from baseline.</li><li>No serious adverse events were observed.</li><li>Patients will be followed for up to seven months post-treatment. To date, none have returned to baseline, including the 17 participants who have reached seven months.</li><li>Topline data from an ongoing Phase 2 randomized, placebo-controlled study, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03241342?titles=astrid&amp;spons=gtx&amp;rank=1\" target=\"_blank\">ASTRID</a>, should be available in Q4.</li><li><a href=\"http://www.gtxinc.com/Pipeline/OstarineMK2866.aspx?Sid=4\" target=\"_blank\">Enobosarm</a>&nbsp;is a non-steroidal androgen receptor agonist also being investigated for the treatment of endocrine-sensitive advanced breast cancer prior to chemotherapy.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3272826-gtxs-enobosarm-shows-treatment-effect-mid-stage-study-postmenopausal-women-stress-urinary\" target=\"_blank\">GTx's enobosarm shows treatment effect in mid-stage study in postmenopausal women with stress urinary incontinence; shares up 14% premarket</a> (June 12, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3358039\" data-linked=\"GTx&#39;s enobosarm continues to demonstrate treatment effect in mid-stage SUI study\" data-tweet=\"$GTXI $ONCT - GTx&#39;s enobosarm continues to demonstrate treatment effect in mid-stage SUI study https://seekingalpha.com/news/3358039-gtxs-enobosarm-continues-to-demonstrate-treatment-effect-in-mid-stage-sui-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3358039-gtxs-enobosarm-continues-to-demonstrate-treatment-effect-in-mid-stage-sui-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3358037\" data-ts=\"1526671072\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SBGL\" target=\"_blank\">SBGL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3358037-reuters-sibanye-ceo-confident-of-lonmin-takeover-despite-cash-burn\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reuters: Sibanye CEO confident of Lonmin takeover despite cash burn</a></h4><ul>     <li>Sibanye-Stillwater (<a href='https://seekingalpha.com/symbol/SBGL' title='Sibanye-Stillwater'>SBGL</a> <font color='red'>-2.6%</font>) <a href=\"https://www.reuters.com/article/platinum-week-sibanye-gold/platinum-week-sibanye-ceo-confident-of-lonmin-takeover-despite-cash-burn-idUSL5N1SO6K0\" target=\"_blank\">remains confident</a> that its planned $386M purchase of Lonmin (<a href='https://seekingalpha.com/symbol/LNMIF' title='Lonmin plc'>OTC:LNMIF</a>) will proceed, CEO&nbsp;Neal Froneman tells Reuters, but the platinum producer must slow its cash burn and achieve certain production targets.</li>     <li>Lonmin said <a href=\"https://seekingalpha.com/news/3356301-sibanye-takeover-still-track-lonmin-says-even-cash-position-weakens\" target=\"_blank\">earlier this week</a> that its net cash position had dropped to $17M from $63M at year-end 2017 but that it intended to recover $47M in H2 of this year; in reaction, Froneman says \"There is a duty on Lonmin management to deliver... I&rsquo;m not panicking. I&rsquo;m very confident in their ability to meet their targets.\"</li>     <li>Froneman also says SBGL, which bought Aquarius Platinum, Anglo American Platinum&rsquo;s Rustenburg assets and U.S.-based Stillwater in recent, will not seek any additional assets in the short term.</li></ul><div class=\"tiny-share-widget\" data-id=\"3358037\" data-linked=\"Reuters: Sibanye CEO confident of Lonmin takeover despite cash burn\" data-tweet=\"$SBGL $SBGL $LNMIF - Reuters: Sibanye CEO confident of Lonmin takeover despite cash burn https://seekingalpha.com/news/3358037-reuters-sibanye-ceo-confident-of-lonmin-takeover-despite-cash-burn?source=tweet\" data-url=\"https://seekingalpha.com/news/3358037-reuters-sibanye-ceo-confident-of-lonmin-takeover-despite-cash-burn\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>45&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3358034\" data-ts=\"1526669719\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UAVS\" target=\"_blank\">UAVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3358034-technology-top-5-gainers-losers-of-2_55-pm-05-18-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top 5 Gainers / Losers as of 2.55 PM (05/18/2018)</a></h4><ul>     <li><strong>Gainers:</strong> <a href='https://seekingalpha.com/symbol/UAVS' title='AgEagle'>UAVS</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/SE' title='Sea Ltd'>SE</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/GDS' title='GDS Holdings'>GDS</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/INVE' title='Identiv, Inc.'>INVE</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/OOMA' title='Ooma'>OOMA</a> <font color='green'>+6%</font>.</li><li><strong>Losers:</strong> <a href='https://seekingalpha.com/symbol/BOXL' title='Boxlight'>BOXL</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/RNET' title='RigNet'>RNET</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/BIDU' title='Baidu, Inc.'>BIDU</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/SGH' title='SMART Global Holdings'>SGH</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/VECO' title='Veeco Instruments Inc.'>VECO</a> <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3358034\" data-linked=\"Technology - Top 5 Gainers / Losers as of 2.55 PM (05/18/2018)\" data-tweet=\"$UAVS $UAVS $SE - Technology - Top 5 Gainers / Losers as of 2.55 PM (05/18/2018) https://seekingalpha.com/news/3358034-technology-top-5-gainers-losers-of-2_55-pm-05-18-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3358034-technology-top-5-gainers-losers-of-2_55-pm-05-18-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3358030\" data-ts=\"1526668436\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/USCR\" target=\"_blank\">USCR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3358030-u-s-concrete-reiterated-buy-da-davidson-despite-short-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. Concrete reiterated a Buy at DA Davidson despite short report</a></h4><ul>     <li>U.S. Concrete (<a href='https://seekingalpha.com/symbol/USCR' title='US Concrete Inc.'>USCR</a> <font color='red'>-2.5%</font>) is <a href=\"https://thefly.com/thestreet/realmoney/index.php/USCRid2733719/USCR-US-Concrete-remains-attractive-investment-opportunity-says-DA-Davidson\" target=\"_blank\">maintained with a Buy rating</a> and $95 price target at DA Davidson, which continues to find the shares attractive following <a href=\"https://seekingalpha.com/news/3357641-u-s-concrete-minus-3-percent-following-negative-spruce-point-tweet\" target=\"_blank\">yesterday's short report</a> from Spruce Point.</li>     <li>While a bear thesis calling an end to the cycle may never completely abate as long as revenue continues to grow, stronger Q2 and Q3 results may help ease concerns regarding cycle momentum, analyst Brent Thielman says.</li>     <li>The firm argues USCR's annual gross margins have been stable for three straight years, albeit with evident quarter-to-quarter fluctuations.</li>     <li>Stifel also reiterates its Buy rating, saying Spruce Point's short thesis is not new and is similar to a short report from another firm released about two years ago; the firm thinks the fundamental outlook for the business remains encouraging.</li></ul><div class=\"tiny-share-widget\" data-id=\"3358030\" data-linked=\"U.S. Concrete reiterated a Buy at DA Davidson despite short report\" data-tweet=\"$USCR - U.S. Concrete reiterated a Buy at DA Davidson despite short report https://seekingalpha.com/news/3358030-u-s-concrete-reiterated-buy-da-davidson-despite-short-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3358030-u-s-concrete-reiterated-buy-da-davidson-despite-short-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3358029\" data-ts=\"1526667941\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIA\" target=\"_blank\">VIA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3358029-bloomberg-court-finds-for-viacom-directors-in-redstone-pay-dispute\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bloomberg: Court finds for Viacom directors in Redstone pay dispute</a></h4><ul>   <li>An appeals court has ruled for the board at Viacom (<a href='https://seekingalpha.com/symbol/VIA' title='Viacom Inc.'>VIA</a> <font color='red'>-2.3%</font>, <a href='https://seekingalpha.com/symbol/VIAB' title='Viacom Inc.'>VIAB</a> <font color='red'>-2.6%</font>), dismissing investor claims that the company overpaid founder Sumner Redstone, Bloomberg reports.</li>    <li>Investors had charged directors with being too complacent about approving $15M in pay and bonuses for Redstone as his mental capacity declined.</li>    <li>But the Delaware Supreme Court upheld a judge's finding that a 2016 settlement resolved those complaints.</li>    <li>The judge who dismissed the Viacom investor claims last year, Judge Andre Bouchard, is presiding over the latest Redstone-related court battle: a lawsuit by CBS looking to strip the Redstone family's voting control of the company.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3357823-cbs-board-votes-strip-redstones-voting-control-company-updated\" target=\"_blank\">CBS board votes to strip Redstones' voting control of company (updated)</a> (May. 17 2018)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3358029\" data-linked=\"Bloomberg: Court finds for Viacom directors in Redstone pay dispute\" data-tweet=\"$VIA $VIA $VIAB - Bloomberg: Court finds for Viacom directors in Redstone pay dispute https://seekingalpha.com/news/3358029-bloomberg-court-finds-for-viacom-directors-in-redstone-pay-dispute?source=tweet\" data-url=\"https://seekingalpha.com/news/3358029-bloomberg-court-finds-for-viacom-directors-in-redstone-pay-dispute\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3358027\" data-ts=\"1526667778\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3358027-wapo-trump-pushed-postmaster-general-to-double-amazon-fees\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WaPo: Trump pushed Postmaster General to double Amazon fees</a></h4><ul><li>        <a href=\"https://www.washingtonpost.com/business/economy/trump-personally-pushed-postmaster-general-to-double-rates-on-amazon-other-firms/2018/05/18/2b6438d2-5931-11e8-858f-12becb4d6067_story.html?noredirect=on&amp;utm_term=.c6562caabd9b\" target=\"_blank\">Washington Post sources</a> say President Trump pushed U.S. Postmaster General Megan Brennan to double the rate charged to Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) and other companies to ship packages.</li><li>               Brennan has resisted, explaining that the arrangements are under contracts and need review by a regulatory commission. &nbsp;&nbsp;</li><li>               Brennan also explained that the relationship with Amazon is beneficial for the Postal Service.&nbsp;</li><li>               Amazon spent $21.7B on shipping in 2017, which includes sorting, delivery center, and transport charges. Analysts think the Postal Service delivers roughly 40% of Amazon packages.&nbsp;</li><li>               The Postal Service reported shipping and package income of $19.5B last year (+12% Y/Y) but lost money mainly due to first-class mail declines.&nbsp;</li><li>               Amazon shares are&nbsp;<font color='red'>down 0.5%</font>&nbsp;to $1,574.43.&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3342966-amazon-minus-4_3-percent-another-trump-tweet\" target=\"_blank\">Amazon -4.3% after another Trump tweet</a> (April 2)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3343344-amazon-minus-1-percent-trump-tweet-suggesting-post-office-collusion\" target=\"_blank\">Amazon -1% on Trump tweet suggesting post office collusion</a> (April 3)</li></ul><div class=\"tiny-share-widget\" data-id=\"3358027\" data-linked=\"WaPo: Trump pushed Postmaster General to double Amazon fees\" data-tweet=\"$AMZN - WaPo: Trump pushed Postmaster General to double Amazon fees https://seekingalpha.com/news/3358027-wapo-trump-pushed-postmaster-general-to-double-amazon-fees?source=tweet\" data-url=\"https://seekingalpha.com/news/3358027-wapo-trump-pushed-postmaster-general-to-double-amazon-fees\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>226&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3358024\" data-ts=\"1526666433\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WMLP-OLD\" target=\"_blank\">WMLP-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3358024-energy-materials-top-5-gainers-losers-of-2-00-pm-05-18-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top 5 Gainers / Losers as of 2:00 PM (05/18/2018)</a></h4><ul>     <li><strong>Gainers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/WMLP-OLD' title='Westmoreland Resource Partners, LP'>WMLP-OLD</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/BRN' title='Barnwell Industries, Inc'>BRN</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/SDR' title='SandRidge Mississippian Trust II'>SDR</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/TGA' title='Transglobe Energy Corp'>TGA</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/LGCY' title='Legacy Reserves Inc'>LGCY</a> <font color='green'>+9%</font>.</li>      <li><strong>Losers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/UPL' title='Ultra Petroleum Corp.'>UPL</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/CHKR' title='Chesapeake Granite Wash Trust'>CHKR</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/GDP' title='Goodrich Petroleum Corp.'>GDP</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/ENSV' title='Enservco Corp.'>ENSV</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/SAEX' title='SAExploration Holdings, Inc.'>SAEX</a> <font color='red'>-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3358024\" data-linked=\"Energy/Materials - Top 5 Gainers / Losers as of 2:00 PM (05/18/2018)\" data-tweet=\"$WMLP-OLD $WMLP-OLD $BRN - Energy/Materials - Top 5 Gainers / Losers as of 2:00 PM (05/18/2018) https://seekingalpha.com/news/3358024-energy-materials-top-5-gainers-losers-of-2-00-pm-05-18-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3358024-energy-materials-top-5-gainers-losers-of-2-00-pm-05-18-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3358023\" data-ts=\"1526665594\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CPB\" target=\"_blank\">CPB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3358023-campbell-soup-back-in-political-crosshairs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Campbell Soup back in the political crosshairs</a></h4><ul> <li>Commerce Secretary Wilbur Ross took a shot at Campbell Soup (<a href='https://seekingalpha.com/symbol/CPB' title='Campbell Soup Company'>CPB</a> <font color='red'>-11.9%</font>) by claiming that the company is blaming tariffs for its lack of profits. While Campbell didn't point to tariffs as the reason behind its $393M net loss in Q1 as indicated by Ross, the subject did come up on the post-earnings conference call.</li> <li>Here's exactly what Campbell CFO Anthony Disilvestreo said on the call (transcript</a>): \"At this stage, given what we know about accelerating cost inflation, in part due to the anticipated impact of import tariffs and the continuing headwind on transportation and logistics cost, we expect our margins will be down in fiscal 2019.\"</li><li>Previously: <a href=\"https://seekingalpha.com/news/3357954-packaged-food-stocks-follow-campbell-soup-lower\" target=\"_blank\">Packaged food stocks follow Campbell Soup lower</a> (May 18)</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3358023\" data-linked=\"Campbell Soup back in the political crosshairs\" data-tweet=\"$CPB - Campbell Soup back in the political crosshairs https://seekingalpha.com/news/3358023-campbell-soup-back-in-political-crosshairs?source=tweet\" data-url=\"https://seekingalpha.com/news/3358023-campbell-soup-back-in-political-crosshairs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3358020\" data-ts=\"1526664580\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AFSI\" target=\"_blank\">AFSI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3358020-kbw-warns-on-icahns-amtrust-involvement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KBW warns on Icahn&#39;s AmTrust involvement</a></h4><ul><li>Should Carl Icahn somehow get in the way of the AmTrust (NASDAQ:<a href='https://seekingalpha.com/symbol/AFSI' title='AmTrust Financial Services, Inc.'>AFSI</a>) going-private deal, shares are far more likely to tumble, rather than go higher, says analyst Meyer Shields.</li><li>He's not sure the Zyskind/Karfunkel family will agree to another boost to their bid, and there's no assurance a third party would step in.</li><li>He continues to rate the shares at Market Perform.</li><li>Source: Bloomberg</li><li>The stock's<font color='green'> up 2.6%&nbsp;</font>today to $13.78.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3357782-amtrust-nearly-7-percent-icahn-discloses-stake\" target=\"_blank\">AmTrust up nearly 7% as Icahn discloses stake</a> (May 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3358020\" data-linked=\"KBW warns on Icahn&#39;s AmTrust involvement\" data-tweet=\"$AFSI - KBW warns on Icahn&#39;s AmTrust involvement https://seekingalpha.com/news/3358020-kbw-warns-on-icahns-amtrust-involvement?source=tweet\" data-url=\"https://seekingalpha.com/news/3358020-kbw-warns-on-icahns-amtrust-involvement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3358014\" data-ts=\"1526663045\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LX\" target=\"_blank\">LX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3358014-financial-top-gainers-losers-of-01-04-pm-05-18-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financial - Top Gainers / Losers as of 01:04 PM (05/18/2018)</a></h4><ul><li><strong>Gainers:</strong> <a href='https://seekingalpha.com/symbol/LX' title='LexinFintech Holdings Ltd. ADS'>LX</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/EHTH' title='eHealth, Inc.'>EHTH</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/DNJR' title='Golden Bull Ltd'>DNJR</a> <font color='green'>+6%</font>.</li><li><strong>Losers:</strong> <a href='https://seekingalpha.com/symbol/CARV' title='Carver Bancorp, Inc.'>CARV</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/FANH' title='Fanhua Inc.'>FANH</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/OPHC' title='OptimumBank Holdings, Inc.'>OPHC</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/PPDF' title='PPDAI Group Inc.'>PPDF</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/SIEB' title='Siebert Financial Corp.'>SIEB</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3358014\" data-linked=\"Financial - Top Gainers / Losers as of 01:04 PM (05/18/2018)\" data-tweet=\"$LX $LX $EHTH - Financial - Top Gainers / Losers as of 01:04 PM (05/18/2018) https://seekingalpha.com/news/3358014-financial-top-gainers-losers-of-01-04-pm-05-18-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3358014-financial-top-gainers-losers-of-01-04-pm-05-18-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3358011\" data-ts=\"1526662812\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PHIO\" target=\"_blank\">PHIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3358011-rxi-pharmas-samcyprone-successful-in-mid-stage-wart-study-shares-ahead-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RXi Pharma&#39;s Samcyprone successful in mid-stage wart study; shares ahead 10%</a></h4><ul><li>Nano cap RXi Pharmaceuticals (RXII <font color='green'>+9.8%</font>) is up on triple normal volume on the heels of its <a href=\"https://seekingalpha.com/pr/17168308-rxi-pharmaceuticals-announces-positive-results-phase-2-trial-samcyprone-treatment-common\" target=\"_blank\">announcement </a>of positive results from a Phase 2 clinical trial, RXI-SCP-1502, evaluating topical med Samcyprone (diphenylcyclopropenone) for the treatment of common warts. The data were presented at the International Investigative Dermatology Conference in Washington, D.C.</li><li>At end of the once-weekly 10-week treatment period, more than 70% of warts were reduced in size by more than 50%. Complete wart clearance was 54% and up to 71% for certain wart types (non-plantar).</li><li>On the safety front, there were no treatment-related serious adverse events nor any dose-limiting toxicities. Most of the adverse events observed were mild skin reactions.</li><li>The company says the results were achieved without any wart preparation, such as soaking or abrasion, typically done before treatment with salicylic acid, the most common first-line treatment.</li><li>Previously: <a href=\"https://seekingalpha.com/news/2996976-rxi-pharma-initiates-mid-stage-study-samcyprone-treatment-warts\" target=\"_blank\">RXi Pharma initiates mid-stage study of Samcyprone for the treatment of warts</a> (Dec. 21, 2015)</li></ul><div class=\"tiny-share-widget\" data-id=\"3358011\" data-linked=\"RXi Pharma&#39;s Samcyprone successful in mid-stage wart study; shares ahead 10%\" data-tweet=\"$PHIO - RXi Pharma&#39;s Samcyprone successful in mid-stage wart study; shares ahead 10% https://seekingalpha.com/news/3358011-rxi-pharmas-samcyprone-successful-in-mid-stage-wart-study-shares-ahead-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3358011-rxi-pharmas-samcyprone-successful-in-mid-stage-wart-study-shares-ahead-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3358010\" data-ts=\"1526662314\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ORPN\" target=\"_blank\">ORPN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3358010-midday-gainers-losers-05-18-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers (05/18/2018)</a></h4><ul>     <li><strong>Gainers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/ORPN' title='Bio Blast Pharma'>ORPN</a> <font color='green'>+31%</font>. <a href='https://seekingalpha.com/symbol/MTEX' title='Mannatech, Incorporated'>MTEX</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/TYHT' title='Shineco, Inc.'>TYHT</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/EOLS' title='Evolus, Inc.'>EOLS</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/QTNT' title='Quotient Limited'>QTNT</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/VLRX' title='Valeritas Holdings, Inc.'>VLRX</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/WMLP-OLD' title='Westmoreland Resource Partners, LP'>WMLP-OLD</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/AQMS' title='Aqua Metals'>AQMS</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/EGY' title='VAALCO Energy, Inc.'>EGY</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/SDR' title='SandRidge Mississippian Trust II'>SDR</a> <font color='green'>+13%</font>.</li>      <li><strong>Losers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/AGRX' title='Agile Therapeutics, Inc.'>AGRX</a> <font color='red'>-74%</font>. <a href='https://seekingalpha.com/symbol/CARV' title='Carver Bancorp, Inc.'>CARV</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/OPK' title='OPKO Health, Inc.'>OPK</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/LIVX' title='LiveXLive Media, Inc.'>LIVX</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/ABEO' title='Abeona Therapeutics Inc.'>ABEO</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/NDRA' title='Endra Life Sciences Inc'>NDRA</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/EIGR' title='Eiger BioPharmaceuticals, Inc.'>EIGR</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/BOXL' title='Boxlight'>BOXL</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/CPB' title='Campbell Soup Company'>CPB</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/FANH' title='Fanhua Inc.'>FANH</a> <font color='red'>-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3358010\" data-linked=\"Midday Gainers / Losers (05/18/2018)\" data-tweet=\"$ORPN $ENLV $MTEX - Midday Gainers / Losers (05/18/2018) https://seekingalpha.com/news/3358010-midday-gainers-losers-05-18-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3358010-midday-gainers-losers-05-18-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:51 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3358008\" data-ts=\"1526661714\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DELL\" target=\"_blank\">DELL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3358008-dell-talking-to-shareholders-full-vmware-merger-dvmtplus-5_8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dell talking to shareholders about full VMware merger; DVMT +5.8%</a></h4><ul><li>        Dell (DVMT) is talking with shareholders to gauge interest in a full merger between the company and VMware (NYSE:<a href='https://seekingalpha.com/symbol/VMW' title='VMware, Inc.'>VMW</a>), according to <a href=\"https://www.cnbc.com/2018/05/18/dell-seeks-feedback-from-dvmt-tracking-stock-holders-on-vmware-merger.html\" target=\"_blank\">CNBC sources</a>.</li><li>               Owners of the tracking stock own shares that track VMware performance but not the rest of Dell.&nbsp;</li><li>               Dell wants to own as much VMware as it can while also cleaning up its capital structure after a string of mergers and spin-outs.&nbsp;</li><li>               In a public filing, Dell says it&rsquo;s still considering an IPO, VMware merger, doing nothing, or exchanging its common stock (held by Michael Dell and Silver Lake) for DVMT shares. &nbsp;&nbsp;</li><li>               DVMT shares are&nbsp;<font color='green'>up 5.8%</font>&nbsp;to $78.63.&nbsp;</li><li>               VMware shares are&nbsp;<font color='green'>up 1.3%</font>.&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3345873-vmware-plus-6_8-percent-dell-leans-reverse-merger\" target=\"_blank\">VMware +6.8% as Dell leans against reverse merger</a> (April 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3358008\" data-linked=\"Dell talking to shareholders about full VMware merger; DVMT +5.8%\" data-tweet=\"$DELL $DELL $VMW - Dell talking to shareholders about full VMware merger; DVMT +5.8% https://seekingalpha.com/news/3358008-dell-talking-to-shareholders-full-vmware-merger-dvmtplus-5_8?source=tweet\" data-url=\"https://seekingalpha.com/news/3358008-dell-talking-to-shareholders-full-vmware-merger-dvmtplus-5_8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:41 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3358006\" data-ts=\"1526661467\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SEE\" target=\"_blank\">SEE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3358006-sealed-air-started-buy-jefferies-best-positioned-to-benefit-from-trends\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sealed Air started at Buy at Jefferies as best positioned to benefit from trends</a></h4><ul>     <li>Sealed Air (<a href='https://seekingalpha.com/symbol/SEE' title='Sealed Air Corporation'>SEE</a> <font color='green'>+1.8%</font>) is initiated with a Buy rating and $53 price target at Jefferies, which says the company is best positioned among packaging companies from changing consumer trends within the domestic sector and growing demand in emerging markets.</li>     <li>Jefferies analyst Daniel Rizzo says the recent pullback in packaging companies makes for an attractive  entry point, citing free cash flow yields averaging 7% and relatively stable end markets.</li>     <li>Rizzo says SEE should offset a lack of pass-thru pricing and a rise in PE costs with cost cuts and price hikes.</li>     <li>Also in the group, Jefferies rates Graphic Packaging (<a href='https://seekingalpha.com/symbol/GPK' title='Graphic Packaging Holding Company'>GPK</a> <font color='green'>+0.4%</font>) as a Buy with a $20 price target, AptarGroup (<a href='https://seekingalpha.com/symbol/ATR' title='AptarGroup Inc.'>ATR</a> <font color='green'>+0.6%</font>) with a Hold and a $99 target, and Bemis (<a href='https://seekingalpha.com/symbol/BMS' title='Bemis Company, Inc.'>BMS</a> <font color='red'>-0.4%</font>) with a Hold and a $46 target.</li>     <li>Source:&nbsp;Bloomberg First Word</li> </ul><div class=\"tiny-share-widget\" data-id=\"3358006\" data-linked=\"Sealed Air started at Buy at Jefferies as best positioned to benefit from trends\" data-tweet=\"$SEE $SEE $GPK - Sealed Air started at Buy at Jefferies as best positioned to benefit from trends https://seekingalpha.com/news/3358006-sealed-air-started-buy-jefferies-best-positioned-to-benefit-from-trends?source=tweet\" data-url=\"https://seekingalpha.com/news/3358006-sealed-air-started-buy-jefferies-best-positioned-to-benefit-from-trends\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3358003\" data-ts=\"1526661010\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NDRA\" target=\"_blank\">NDRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3358003-endra-life-sciences-continues-post-ipo-stumble-down-14\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ENDRA Life Sciences continues post-IPO stumble, down 14%</a></h4><ul><li>Thinly traded nano cap <a href=\"https://endrainc.com/\" target=\"_blank\">ENDRA Life Sciences</a> (<a href='https://seekingalpha.com/symbol/NDRA' title='Endra Life Sciences Inc'>NDRA</a> <font color='red'>-14%</font>) adds to its retreat since <a href=\"https://seekingalpha.com/pr/16826108-endra-life-sciences-inc-prices-initial-public-offering\" target=\"_blank\">debuting at $5/unit on May 9</a>. Each unit consisted of one share of common stock and one five-year warrant to purchase one share of common at $6.25. Shares are currently exchanging hands at $1.93.</li><li>The company develops technologies that improve the performance of ultrasound systems.</li></ul><div class=\"tiny-share-widget\" data-id=\"3358003\" data-linked=\"ENDRA Life Sciences continues post-IPO stumble, down 14%\" data-tweet=\"$NDRA - ENDRA Life Sciences continues post-IPO stumble, down 14% https://seekingalpha.com/news/3358003-endra-life-sciences-continues-post-ipo-stumble-down-14?source=tweet\" data-url=\"https://seekingalpha.com/news/3358003-endra-life-sciences-continues-post-ipo-stumble-down-14\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:30 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3358002\" data-ts=\"1526660614\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRMW\" target=\"_blank\">PRMW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3358002-primo-announces-pricing-of-follow-on-public-offering-of-common-stock\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Primo announces pricing of follow-on public offering of common stock</a></h4><ul>     <li>Primo Water (<a href='https://seekingalpha.com/symbol/PRMW' title='Primo Water'>PRMW</a> <font color='green'>+4%</font>) prices underwritten public offering of 4.643M shares of its common stock at a price of $14.00/share to the public.</li>     <li>The offering is expected to close on or about May 22, 2018, subject to the satisfaction of customary closing conditions.</li><li><a href=\"https://seekingalpha.com/pr/17168007-primo-announces-pricing-follow-public-offering-common-stock\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3358002\" data-linked=\"Primo announces pricing of follow-on public offering of common stock\" data-tweet=\"$PRMW - Primo announces pricing of follow-on public offering of common stock https://seekingalpha.com/news/3358002-primo-announces-pricing-of-follow-on-public-offering-of-common-stock?source=tweet\" data-url=\"https://seekingalpha.com/news/3358002-primo-announces-pricing-of-follow-on-public-offering-of-common-stock\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357993\" data-ts=\"1526660201\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RAVN\" target=\"_blank\">RAVN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357993-raven-industries-slides-10-despite-strong-margins\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Raven Industries slides 10% despite strong margins</a></h4><ul><li>Raven Industries (<a href='https://seekingalpha.com/symbol/RAVN' title='Raven Industries, Inc.'>RAVN</a> <font color='red'>-10.4%</font>) <a href=\"https://seekingalpha.com/filing/4030491\" target=\"_blank\">reports Q1</a> revenue growth of 18.8% Y/Y to $111.13M of which Applied Technology was $40.4M (-0.1% Y/Y); Engineered Films $60M (+37.7% Y/Y) &amp; Aerostar $10.9M (+13.5% Y/Y).</li><li>Segment operating margin: Applied Technology <font color='green'>increased 620 bps</font> to 39.4%; Engineered Films <font color='green'>increased 200 bps</font> to 22% &amp; Aerostar <font color='green'>increased 1,090 bps</font> to 25.7%.</li><li>Segment EBIDTA margin: Applied Technology <font color='green'>increased 600 bps</font> to 41.3%; Engineered Films <font color='green'>increased 110 bps</font> to 25.9% &amp; Aerostar <font color='green'>increased 860 bps</font> to 27.7%.</li><li>Cash proceeds from the sale of SST &amp; continued strength in operating cash flows principally drove the  increase in cash &amp; equivalents by 26.6% Q/Q to   $51.3M.</li><li>Net working capital of 24.1% &amp; expects $22M of Capex for 2019.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3357819-raven-beats-0_12-misses-revenue\" target=\"_blank\">Raven beats by $0.12, misses on revenue</a> (May. 17 2018)</li></ul><div class=\"tiny-share-widget\" data-id=\"3357993\" data-linked=\"Raven Industries slides 10% despite strong margins\" data-tweet=\"$RAVN - Raven Industries slides 10% despite strong margins https://seekingalpha.com/news/3357993-raven-industries-slides-10-despite-strong-margins?source=tweet\" data-url=\"https://seekingalpha.com/news/3357993-raven-industries-slides-10-despite-strong-margins\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:16 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3358000\" data-ts=\"1526659636\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MLNX\" target=\"_blank\">MLNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3358000-piper-jaffray-upgrades-mellanox-to-15-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Piper Jaffray upgrades Mellanox to 15% upside</a></h4><ul><li>        Piper Jaffray <a href=\"https://www.streetinsider.com/Analyst+Comments/Piper+Jaffray+Upgrades+Mellanox+Technologies+%28MLNX%29+to+Overweight/14211829.html\" target=\"_blank\">upgrades</a> Mellanox Tech (NASDAQ:<a href='https://seekingalpha.com/symbol/MLNX' title='Mellanox Technologies, Ltd.'>MLNX</a>) from Neutral to Overweight and raises the price target from $84 to $100.</li><li>               New target represents a 15% upside to yesterday&rsquo;s close.&nbsp;</li><li>               Mellanox shares are&nbsp;<font color='red'>down 1.2%</font>&nbsp;to $86.02.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3358000\" data-linked=\"Piper Jaffray upgrades Mellanox to 15% upside\" data-tweet=\"$MLNX - Piper Jaffray upgrades Mellanox to 15% upside https://seekingalpha.com/news/3358000-piper-jaffray-upgrades-mellanox-to-15-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3358000-piper-jaffray-upgrades-mellanox-to-15-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357998\" data-ts=\"1526659390\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DE\" target=\"_blank\">DE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357998-deereplus-6-on-pledge-to-raise-equipment-prices-to-fight-rising-costs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deere +6% on pledge to raise equipment prices to fight rising costs</a></h4><ul>     <li>Deere (<a href='https://seekingalpha.com/symbol/DE' title='Deere & Company'>DE</a> <font color='green'>+6.4%</font>) says it will <a href=\"https://www.bloomberg.com/news/articles/2018-05-18/deere-raises-profit-forecast-as-farm-recovery-gathers-pace\" target=\"_blank\">cut costs and raise equipment prices</a> this year to protect profits, sending shares sharply higher.</li>     <li>Higher freight and raw materials costs caused DE to <a href=\"https://seekingalpha.com/news/3357881-deere-dips-missing-estimates\" target=\"_blank\">miss Q2 earnings estimates</a> but the company now expects full-year adjusted earnings of $3.1B, higher than $2.85B forecast earlier, with full-year equipment sales forecast to rise by ~30% Y/Y to $33.7B and Q3 equipment sales jumping 35%.</li>     <li>DE's cost of sales soared 35% percent in the quarter from a year ago, and it expects input costs during the year to come in higher than its earlier outlook.</li><li>Today's stock surge may be taking analysts by surprise who were <a href=\"https://seekingalpha.com/news/3357922-deere-slightly-lower-analysts-digest-earnings-miss-tepid-guidance\" target=\"_blank\">underwhelmed</a> by DE's Q2 results and \"tepid\"guidance.</li></ul><div class=\"tiny-share-widget\" data-id=\"3357998\" data-linked=\"Deere +6% on pledge to raise equipment prices to fight rising costs\" data-tweet=\"$DE - Deere +6% on pledge to raise equipment prices to fight rising costs https://seekingalpha.com/news/3357998-deereplus-6-on-pledge-to-raise-equipment-prices-to-fight-rising-costs?source=tweet\" data-url=\"https://seekingalpha.com/news/3357998-deereplus-6-on-pledge-to-raise-equipment-prices-to-fight-rising-costs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357995\" data-ts=\"1526659251\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTEX\" target=\"_blank\">MTEX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357995-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MTEX' title='Mannatech, Incorporated'>MTEX</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/ZX' title='China Zenix Auto International'>ZX</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/CAAS' title='China Automotive Systems, Inc.'>CAAS</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/WPRT' title='Westport Fuel Systems, Inc.'>WPRT</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CPB' title='Campbell Soup Company'>CPB</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/ANFI' title='Amira Nature Foods'>ANFI</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/MYE' title='Myers Industries, Inc.'>MYE</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3357995\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$MTEX $MTEX $ZXAIY - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3357995-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3357995-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357991\" data-ts=\"1526658142\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCAU\" target=\"_blank\">FCAU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357991-fiat-chrysler-lower-on-another-emissions-cheating-reveal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fiat Chrysler lower on another emissions cheating reveal</a></h4><ul> <li>Fiat Chrysler (NYSE:<a href='https://seekingalpha.com/symbol/FCAU' title='Fiat Chrysler Automobiles NV'>FCAU</a>) is <font color='red'>down 1.66%</font> after a <a href=\"https://www.bloomberg.com/news/articles/2018-05-18/fiat-chrysler-supplier-emails-suggest-diesel-cheat-known-in-2010\" target=\"_blank\">report</a> from Bloomberg News indicates that the automaker discussed using illegal software to cheat emissions tests as far back as 2010.</li> <li>A Fiat employee tried to convince an exec at a supplier in e-mails that the software shouldn't be considered a mechanism to fool emissions tests.</li> <li>The e-mails were release today in testimony at a federal court in San Francisco.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3357991\" data-linked=\"Fiat Chrysler lower on another emissions cheating reveal\" data-tweet=\"$FCAU - Fiat Chrysler lower on another emissions cheating reveal https://seekingalpha.com/news/3357991-fiat-chrysler-lower-on-another-emissions-cheating-reveal?source=tweet\" data-url=\"https://seekingalpha.com/news/3357991-fiat-chrysler-lower-on-another-emissions-cheating-reveal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:42 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357987\" data-ts=\"1526657099\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NXPI\" target=\"_blank\">NXPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357987-nxp-qualcomm-gain-on-encouraging-word-out-of-beijing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NXP, Qualcomm gain on encouraging word out of Beijing</a></h4><ul><li>        NXP Semiconductors (NASDAQ:<a href='https://seekingalpha.com/symbol/NXPI' title='NXP Semiconductors'>NXPI</a>)&nbsp;<font color='green'>gains 4.8%</font>&nbsp;on <a href=\"https://www.wsj.com/articles/china-drops-probe-into-u-s-sorghum-shipments-1526629000\" target=\"_blank\">encouraging word</a> out of Beijing about its acquisition by Qualcomm (NASDAQ:<a href='https://seekingalpha.com/symbol/QCOM' title='Qualcomm Inc.'>QCOM</a>).</li><li>               The WSJ quotes a Beijing official: &ldquo;The Qualcomm/NXP deal is looking more optimistic now.&rdquo;&nbsp;</li><li>               Qualcomm shares are<font color='green'> up 1.6%</font>&nbsp;to $57.87.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3357987\" data-linked=\"NXP, Qualcomm gain on encouraging word out of Beijing\" data-tweet=\"$NXPI $NXPI $QCOM - NXP, Qualcomm gain on encouraging word out of Beijing https://seekingalpha.com/news/3357987-nxp-qualcomm-gain-on-encouraging-word-out-of-beijing?source=tweet\" data-url=\"https://seekingalpha.com/news/3357987-nxp-qualcomm-gain-on-encouraging-word-out-of-beijing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>45&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357984\" data-ts=\"1526657083\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRK\" target=\"_blank\">MRK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357984-merck-recovers-from-fda-alert-stoked-selloff\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Merck recovers from FDA alert-stoked selloff</a></h4><ul><li>Merck (<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a> <font color='green'>+0.1%</font>) has recovered from a spike in selling apparently caused by an FDA alert (unable to locate) on an efficiency issue found for certain patients being treated with Keytruda (pembrolizumab) or Roche's (<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding Ltd ADR'>OTCQX:RHHBY</a> <font color='green'>+0.7%</font>) Tecentriq (atezolizumab). Shares were down almost&nbsp;<font color='red'>3%&nbsp;</font>before recovering.</li><li>Roche did not experience any selling pressure.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3357984\" data-linked=\"Merck recovers from FDA alert-stoked selloff\" data-tweet=\"$MRK $MRK $RHHBY - Merck recovers from FDA alert-stoked selloff https://seekingalpha.com/news/3357984-merck-recovers-from-fda-alert-stoked-selloff?source=tweet\" data-url=\"https://seekingalpha.com/news/3357984-merck-recovers-from-fda-alert-stoked-selloff\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357985\" data-ts=\"1526656754\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SSNNF\" target=\"_blank\">SSNNF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357985-dram-prices-decline-micronminus-2_8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DRAM prices decline, Micron -2.8%</a></h4><ul><li>        DRAM market dynamics &ldquo;have rather abruptly shifted,&rdquo; <a href=\"https://twitter.com/thenotablecalls/status/997462112002887680\" target=\"_blank\">according to Notable Calls</a> citing a &ldquo;well respected Technology shop.&rdquo;</li><li>               The pricing looks less bullish with DRAM falling below expectations.&nbsp;</li><li>               Notable Calls <a href=\"https://twitter.com/thenotablecalls/status/997466765339840512\" target=\"_blank\">also says</a> Nomura says DRAM pricing declined W/W, according to the firm&rsquo;s checks.&nbsp;</li><li>                  Top DRAM players: Samsung&nbsp;(<a href='https://seekingalpha.com/symbol/SSNNF' title='Samsung Electronics Co., Ltd.'>OTC:SSNNF</a>, <a href='https://seekingalpha.com/symbol/SSNLF' title='Samsung Electronics Co., Ltd.'>OTC:SSNLF</a>) <br />SK Hynix&nbsp;(<a href='https://seekingalpha.com/symbol/HXSCF' title='SK Hynix, Inc.'>OTC:HXSCF</a>, <a href='https://seekingalpha.com/symbol/HXSCL' title='SK Hynix, Inc.'>OTC:HXSCL</a>), and Micron (<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a> <font color='red'>-2.6%</font>).    </li><li>               Micron has its analyst day event on Monday, which could become a catalyst. &nbsp;&nbsp;</li><li>                  Micron shares are&nbsp;<font color='red'>down 2.8%</font>&nbsp;to $53.24.&nbsp;&nbsp;&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3357918-rbc-sees-analyst-day-catalyst-micron\" target=\"_blank\">RBC sees analyst day as catalyst for Micron</a> (May 18)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3357943-chip-stocks-slump-applied-materials-earnings-guidance\" target=\"_blank\">Chip stocks slump on Applied Materials earnings, guidance</a> (May 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3357985\" data-linked=\"DRAM prices decline, Micron -2.8%\" data-tweet=\"$SSNNF $SSNNF $SSNLF - DRAM prices decline, Micron -2.8% https://seekingalpha.com/news/3357985-dram-prices-decline-micronminus-2_8?source=tweet\" data-url=\"https://seekingalpha.com/news/3357985-dram-prices-decline-micronminus-2_8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>143&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357977\" data-ts=\"1526656368\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ORPN\" target=\"_blank\">ORPN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357977-healthcare-top-5-gainers-losers-of-11-10-05-18-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:10 AM (05/18/2018)</a></h4><ul><li><strong>Gainers:</strong> <a href='https://seekingalpha.com/symbol/ORPN' title='Bio Blast Pharma'>ORPN</a> <font color='green'>+38%</font>. <a href='https://seekingalpha.com/symbol/EOLS' title='Evolus, Inc.'>EOLS</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/VLRX' title='Valeritas Holdings, Inc.'>VLRX</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/TYHT' title='Shineco, Inc.'>TYHT</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/QTNT' title='Quotient Limited'>QTNT</a> <font color='green'>+13%</font>.</li><li><strong>Losers:</strong> <a href='https://seekingalpha.com/symbol/AGRX' title='Agile Therapeutics, Inc.'>AGRX</a> <font color='red'>-76%</font>. <a href='https://seekingalpha.com/symbol/OPK' title='OPKO Health, Inc.'>OPK</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/EIGR' title='Eiger BioPharmaceuticals, Inc.'>EIGR</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/ABEO' title='Abeona Therapeutics Inc.'>ABEO</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/EDIT' title='Editas Medicine'>EDIT</a> <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3357977\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:10 AM (05/18/2018)\" data-tweet=\"$ORPN $ENLV $EOLS - Healthcare - Top 5 Gainers / Losers as of 11:10 AM (05/18/2018) https://seekingalpha.com/news/3357977-healthcare-top-5-gainers-losers-of-11-10-05-18-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3357977-healthcare-top-5-gainers-losers-of-11-10-05-18-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357972\" data-ts=\"1526655823\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRS\" target=\"_blank\">AMRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357972-amyris-chevron-to-develop-and-market-renewable-base-oil-technologies\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amyris, Chevron to develop and market renewable base oil technologies</a></h4><ul>     <li>Amyris (<a href='https://seekingalpha.com/symbol/AMRS' title='Amyris, Inc.'>AMRS</a> <font color='green'>+4.5%</font>) moves sharply higher after announcing an agreement with Chevron (<a href='https://seekingalpha.com/symbol/CVX' title='Chevron Corporation'>CVX</a> <font color='red'>-0.9%</font>) to <a href=\"https://seekingalpha.com/pr/17168076-amyris-sustainable-lubricants-joint-venture-company-novvi-chevron-enter-agreement-develop\" target=\"_blank\">jointly develop and market</a> new renewable base oil technologies; financial terms are not disclosed.</li>     <li>AMRS, CVX and other firms already market renewable oils through their Novvi joint venture, and the new agreement expands the relationship to include base oil development and commercialization.</li>     <li>The companies say the venture will combine Novvi's expertise in working with renewable feeds with CVX's expertise in hydroprocessing technology</li> </ul><div class=\"tiny-share-widget\" data-id=\"3357972\" data-linked=\"Amyris, Chevron to develop and market renewable base oil technologies\" data-tweet=\"$AMRS $AMRS $CVX - Amyris, Chevron to develop and market renewable base oil technologies https://seekingalpha.com/news/3357972-amyris-chevron-to-develop-and-market-renewable-base-oil-technologies?source=tweet\" data-url=\"https://seekingalpha.com/news/3357972-amyris-chevron-to-develop-and-market-renewable-base-oil-technologies\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357970\" data-ts=\"1526655791\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZEN\" target=\"_blank\">ZEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357970-stifel-raises-zendesk-target-to-9-downside-sharesplus-2_8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stifel raises its Zendesk target to 9% downside; shares +2.8%</a></h4><ul><li>        Stifel <a href=\"https://www.streetinsider.com/Analyst+PT+Change/Zendesk+%28ZEN%29+PT+Raised+to+%2450+at+Stifel/14211635.html\" target=\"_blank\">maintains</a> a Hold rating but raises its Zendesk (NYSE:<a href='https://seekingalpha.com/symbol/ZEN' title='Zendesk, Inc.'>ZEN</a>) price target from $45 to $50.</li><li>               The new target represents a 9% downside to yesterday&rsquo;s close.&nbsp;</li><li>               Zendesk share are&nbsp;<font color='green'>up 2.8%</font>&nbsp;to $56.64.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3357970\" data-linked=\"Stifel raises its Zendesk target to 9% downside; shares +2.8%\" data-tweet=\"$ZEN - Stifel raises its Zendesk target to 9% downside; shares +2.8% https://seekingalpha.com/news/3357970-stifel-raises-zendesk-target-to-9-downside-sharesplus-2_8?source=tweet\" data-url=\"https://seekingalpha.com/news/3357970-stifel-raises-zendesk-target-to-9-downside-sharesplus-2_8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357968\" data-ts=\"1526655551\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ORPN\" target=\"_blank\">ORPN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357968-bioblast-pharma-up-33\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bioblast Pharma up 33%</a></h4><ul><li>Thinly traded nano cap Bioblast Pharma (<a href='https://seekingalpha.com/symbol/ORPN' title='Bio Blast Pharma'>ORPN</a> <font color='green'>+33.3%</font>) is up on more than a 10x surge in volume.</li><li>No particular news accounts for the action, but the company is facing a capital raise. At year-end 2017, it had ~$3.5M in cash and equivalents while operations consumed ~$6.4M during the year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3357968\" data-linked=\"Bioblast Pharma up 33%\" data-tweet=\"$ORPN $ENLV - Bioblast Pharma up 33% https://seekingalpha.com/news/3357968-bioblast-pharma-up-33?source=tweet\" data-url=\"https://seekingalpha.com/news/3357968-bioblast-pharma-up-33\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357956\" data-ts=\"1526654661\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TARO\" target=\"_blank\">TARO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357956-on-taro-pharmaceutical-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Taro Pharmaceutical Q4 results</a></h4><ul><li>Taro Pharmaceutical (<a href='https://seekingalpha.com/symbol/TARO' title='Taro Pharmaceutical Industries Ltd'>TARO</a> <font color='red'>-1.4%</font>) <a href=\"https://seekingalpha.com/filing/4030535\" target=\"_blank\">reports Q4</a> revenue decrease of 10.8% Y/Y to $175.22M; despite an increase in  overall volumes revenues were down due to continuing increased competition and the challenging  pricing environment, particularly in the U.S.</li><li>Q1 Margins: Gross <font color='red'>declined 530 bps</font> to 67.9% &amp; operating <font color='red'>declines 910 bps</font> to 42.7%.</li><li>Q1 Expenses:&nbsp;R&amp;D  was $20.3M (+2% Y/Y) &amp; S,G&amp;A was $23.8M (+17.8% Y/Y).</li><li>Cash flow by operations for the year was  $323.7M (-26% Y/Y); Cash, including short-term &amp; long-term bank  deposits &amp; marketable securities, increased $190.8M to $1.6B, as cash reflects the $107M impact from the company&rsquo;s share repurchase program.</li><li>The company repurchased 1.09M shares at an average price of $102.52.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3357818-taro-pharmaceutical-reports-q4-results\" target=\"_blank\">Taro Pharmaceutical reports Q4 results</a> (May. 17 2018)</li></ul><div class=\"tiny-share-widget\" data-id=\"3357956\" data-linked=\"More on Taro Pharmaceutical Q4 results\" data-tweet=\"$TARO - More on Taro Pharmaceutical Q4 results https://seekingalpha.com/news/3357956-on-taro-pharmaceutical-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3357956-on-taro-pharmaceutical-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:44 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357963\" data-ts=\"1526654559\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABEO\" target=\"_blank\">ABEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357963-abeo-down-12-on-gene-therapy-data-in-sanfilippo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Abeo down 12% on gene therapy data in Sanfilippo</a></h4><ul><li>Abeona Therapeutics (<a href='https://seekingalpha.com/symbol/ABEO' title='Abeona Therapeutics Inc.'>ABEO</a> <font color='red'>-11.5%</font>) is down on a 50% spike in volume following its release of <a href=\"https://seekingalpha.com/pr/17168186-abeona-therapeutics-provides-clinical-update-mps-iiia-gene-therapy-trial-21st-annual-asgct\" target=\"_blank\">updated data</a> from a Phase 1/2 clinical trial assessing gene therapy ABO-102 in patients with <a href=\"https://medlineplus.gov/ency/article/001210.htm\" target=\"_blank\">Sanfilippo syndrome type A</a> (MPS III A), a rare inherited disorder characterized by the buildup of sugar molecules in tissues and organs leading to a range of health problems.</li><li>To date, 11 patients have received a single intravenous injection of ABO-102 which delivers the missing gene associated with the disease.</li><li>Reductions in heparan sulfate, the hallmark sugar molecule in MPS III A, in cerebral spinal fluid were 25.8 - 67.1% at day 30 (3 - 4 patients), 58.7 - 83.3% at day 180 (1 -3 patients) and 65.7 - 69.3% at day 360 (2 patients).</li><li>In urine, the reductions in heparan sulfate ranged from 29.2 - 90.3% from day 30 to day 540.</li><li>Patients experienced durable biophysical reductions of disease burden, including reductions in liver volume.</li><li>On the safety front, no treatment-related serious adverse events were observed.</li><li>Investors appeared to have sold on the news since shares were initially down almost&nbsp;<font color='red'>26%</font>&nbsp;before recovering.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3328929-abeonas-gene-therapy-candidate-sanfilippo-b-shows-encouraging-effect-first-patient-shares-12\" target=\"_blank\">Abeona's gene therapy candidate for Sanfilippo B shows encouraging effect in first patient; shares up 12%</a> (Feb. 7)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3331505-abeona-rebounds-bearish-report-stoked-selloff-1-percent\" target=\"_blank\">Abeona rebounds from bearish report-stoked selloff, up 1%</a> (Feb. 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3357963\" data-linked=\"Abeo down 12% on gene therapy data in Sanfilippo\" data-tweet=\"$ABEO - Abeo down 12% on gene therapy data in Sanfilippo https://seekingalpha.com/news/3357963-abeo-down-12-on-gene-therapy-data-in-sanfilippo?source=tweet\" data-url=\"https://seekingalpha.com/news/3357963-abeo-down-12-on-gene-therapy-data-in-sanfilippo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357962\" data-ts=\"1526654478\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CUI\" target=\"_blank\">CUI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357962-cui-global-subsidiary-secures-second-biomethane-contract\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CUI Global Subsidiary Secures Second Biomethane Contract</a></h4><ul>     <li>CUI Global's (<a href='https://seekingalpha.com/symbol/CUI' title='CUI Global, Inc.'>CUI</a> <font color='green'>+1.4%</font>) subsidiary, Orbital Gas Systems Ltd., was awarded a second contract valued in excess of $500K for a biomethane-to-grid unit by a major European industrial company.</li><li>The new contract calls for the provision of one biomethane-to-grid unit to be delivered in 2018.</li>     <li><a href=\"https://seekingalpha.com/pr/17166529-cui-global-subsidiary-orbital-gas-u-k-secures-second-biomethane-contract-major-european\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3357962\" data-linked=\"CUI Global Subsidiary Secures Second Biomethane Contract\" data-tweet=\"$CUI - CUI Global Subsidiary Secures Second Biomethane Contract https://seekingalpha.com/news/3357962-cui-global-subsidiary-secures-second-biomethane-contract?source=tweet\" data-url=\"https://seekingalpha.com/news/3357962-cui-global-subsidiary-secures-second-biomethane-contract\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357961\" data-ts=\"1526653926\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDP\" target=\"_blank\">MDP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357961-report-meredith-sees-200m-bids-for-time-fortune-money-brands\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Report: Meredith sees $200M bids for Time, Fortune/Money brands</a></h4><ul>   <li>Meredith (<a href=\"http://seekingalpha.com/symbol/MDP\" target=\"_blank\">MDP</a> <font color='green'>+4%</font>) is <a href=\"https://nypost.com/2018/05/17/bidding-for-time-fortune-and-money-surprisingly-strong/\" target=\"_blank\">seeing healthy bidding</a> for the magazine brand divestments tied to its acquisition of Time Inc., the <i>New York Post</i> reports.</li>    <li>With first-round bids having arrived last week, <i>Time</i> has drawn bids of close to $200M, and so has a combination of <i>Fortune</i> and <i>Money.</i></li>    <li><i>Sports Illustrated</i> has reportedly been seeing bids close to that amount as well, in a sale handled by Houlihan Lokey.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3357961\" data-linked=\"Report: Meredith sees $200M bids for Time, Fortune/Money brands\" data-tweet=\"$MDP - Report: Meredith sees $200M bids for Time, Fortune/Money brands https://seekingalpha.com/news/3357961-report-meredith-sees-200m-bids-for-time-fortune-money-brands?source=tweet\" data-url=\"https://seekingalpha.com/news/3357961-report-meredith-sees-200m-bids-for-time-fortune-money-brands\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357960\" data-ts=\"1526653917\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GME\" target=\"_blank\">GME</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357960-gamestop-lower-baml-stays-negative\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GameStop lower as BAML stays negative</a></h4><ul> <li>GameStop (NYSE:<a href='https://seekingalpha.com/symbol/GME' title='GameStop Corp.'>GME</a>) is <font color='red'>down 5.85%</font> after Bank of America Merrill Lynch reiterates an Underperform rating on the retailer.</li> <li>The investment firm points to weak software sales data for April in staying negative on GameStop.</li> <li>BAML's price target on GameStop is $10. The 52-week low on GameStop is $12.20.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3357960\" data-linked=\"GameStop lower as BAML stays negative\" data-tweet=\"$GME - GameStop lower as BAML stays negative https://seekingalpha.com/news/3357960-gamestop-lower-baml-stays-negative?source=tweet\" data-url=\"https://seekingalpha.com/news/3357960-gamestop-lower-baml-stays-negative\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357955\" data-ts=\"1526653047\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TYHT\" target=\"_blank\">TYHT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357955-shineco-up-21-on-bullish-fq3-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shineco up 21% on bullish FQ3 results</a></h4><ul><li>Thinly traded nano cap Shineco (<a href='https://seekingalpha.com/symbol/TYHT' title='Shineco, Inc.'>TYHT</a> <font color='green'>+20.6%</font>) is up on a whopping 41x surge in volume after releasing <a href=\"https://seekingalpha.com/pr/17167738-shineco-inc-reports-third-quarter-2018-financial-results\" target=\"_blank\">positive fiscal Q3 results</a>.</li><li>Revenue was up 68% to $13.34M while earnings jumped 137% to $4.55M.</li><li>The key driver was its Luobuma herbal medicine line which generated $5.48M in sales, up 389%. The increase was primarily due to the establishment of a new subsidiary, Xinjiang Taihe, which generated revenue of ~$5.2M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3357955\" data-linked=\"Shineco up 21% on bullish FQ3 results\" data-tweet=\"$TYHT - Shineco up 21% on bullish FQ3 results https://seekingalpha.com/news/3357955-shineco-up-21-on-bullish-fq3-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3357955-shineco-up-21-on-bullish-fq3-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357954\" data-ts=\"1526652972\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CPB\" target=\"_blank\">CPB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357954-packaged-food-stocks-follow-campbell-soup-lower\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Packaged food stocks follow Campbell Soup lower</a></h4><ul> <li>Campbell Soup (NYSE:<a href='https://seekingalpha.com/symbol/CPB' title='Campbell Soup Company'>CPB</a>) is&nbsp;<font color='red'>down 11.9%</font>&nbsp;on a post-earnings slide that worsened during the company's conference call when it warned of the negative impact of tariffs on margins this year.</li> <li>The tariff warning and soft overall Q1 report from Campbell Soup is dragging parts of the packaged foods sector down.</li> <li>Notable movers include B&amp;G Foods (NYSE:<a href='https://seekingalpha.com/symbol/BGS' title='B&G Foods, Inc.'>BGS</a>)&nbsp;<font color='red'>-6.1%</font>, General Mills (NYSE:<a href='https://seekingalpha.com/symbol/GIS' title='General Mills, Inc.'>GIS</a>)<font color='red'> -3.8%</font>, J.M. Smucker (NYSE:<a href='https://seekingalpha.com/symbol/SJM' title='J. M. Smucker Company'>SJM</a>)&nbsp;<font color='red'>-3.3%</font>, McCormick (NYSE:<a href='https://seekingalpha.com/symbol/MKC' title='McCormick & Company, Inc.'>MKC</a>)&nbsp;<font color='red'>-3.1%</font>, Kellogg (NYSE:<a href='https://seekingalpha.com/symbol/K' title='Kellogg Company'>K</a>)&nbsp;<font color='red'>-2.6%</font>, Flower Foods (NYSE:<a href='https://seekingalpha.com/symbol/FLO' title='Flowers Foods, Inc.'>FLO</a>)&nbsp;<font color='red'>-2.2%</font>, ConAgra Brands (NYSE:<a href='https://seekingalpha.com/symbol/CAG' title='ConAgra Brands, Inc.'>CAG</a>)<font color='red'> -2.2%</font>&nbsp;and Hostess Brands (NASDAQ:<a href='https://seekingalpha.com/symbol/TWNK' title='Hostess Brands, Inc.'>TWNK</a>)&nbsp;<font color='red'>-1.5%</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3357866-campbell-soup-ceo-retires\" target=\"_blank\">Campbell Soup CEO retires</a> (May 18)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3357874-campbell-soup-lower-5-percent-results-ceo-exit\" target=\"_blank\">Campbell Soup lower by 5% after results, CEO exit</a> (May 18)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3357954\" data-linked=\"Packaged food stocks follow Campbell Soup lower\" data-tweet=\"$CPB $CPB $BGS - Packaged food stocks follow Campbell Soup lower https://seekingalpha.com/news/3357954-packaged-food-stocks-follow-campbell-soup-lower?source=tweet\" data-url=\"https://seekingalpha.com/news/3357954-packaged-food-stocks-follow-campbell-soup-lower\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>71&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357949\" data-ts=\"1526652448\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGRX\" target=\"_blank\">AGRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357949-agile-therapeutics-down-76-on-additional-work-needed-for-u-s-approval-of-twirla\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Agile Therapeutics down 76% on additional work needed for U.S. approval of Twirla</a></h4><ul><li>Thinly traded nano cap Agile Therapeutics (<a href='https://seekingalpha.com/symbol/AGRX' title='Agile Therapeutics, Inc.'>AGRX</a> <font color='red'>-75.9%</font>) is down on a 20x surge in volume in response to its <a href=\"https://seekingalpha.com/pr/17168009-agile-therapeutics-inc-provides-regulatory-update-twirla-ag200minus-15-prevention-pregnancy\" target=\"_blank\">announcement </a>of FDA feedback related to its second CRL for contraceptive patch Twirla.</li><li>Per the official minutes from their April 16 meeting, the agency informed the company that it still has \"significant concerns\" regarding the adhesion of Twirla, a deficiency that it believes cannot be adequately addressed through its proposed patient compliance programs so the product needs reformulating followed by a formal adhesion study to confirm its performance.</li><li>The FDA also wants bioequivalence data on the new formulation versus the original. If bioequivalence cannot be demonstrated, then a new Phase 3 trial will be needed.</li><li>In addition, there may be more work required to address manufacturing issues.</li><li>The agency indicated that an advisory committee review would be probable upon the resubmission and acceptance of an updated application.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3319828-agile-strikes-u-s-ok-contraceptive-patch-twirla\" target=\"_blank\">Agile strikes out again on U.S. OK of contraceptive patch Twirla</a> (Dec. 22, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3357949\" data-linked=\"Agile Therapeutics down 76% on additional work needed for U.S. approval of Twirla\" data-tweet=\"$AGRX - Agile Therapeutics down 76% on additional work needed for U.S. approval of Twirla https://seekingalpha.com/news/3357949-agile-therapeutics-down-76-on-additional-work-needed-for-u-s-approval-of-twirla?source=tweet\" data-url=\"https://seekingalpha.com/news/3357949-agile-therapeutics-down-76-on-additional-work-needed-for-u-s-approval-of-twirla\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357950\" data-ts=\"1526652414\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTEX\" target=\"_blank\">MTEX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357950-mannatech-tenders-for-shares-stock-jumps-24\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mannatech tenders for shares; stock jumps 24%</a></h4><ul><li>Mannatech (<a href='https://seekingalpha.com/symbol/MTEX' title='Mannatech, Incorporated'>MTEX</a> <font color='green'>+23.9%</font>) commences a Dutch auction for up to $16M in common stock between $18.50 and $21.00 per share.</li><li>At $20 per share, that would be 800K shares vs. current float of 2.7M.</li><li>Today's gain brings the price to $19.70.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17168181-mannatech-commences-cash-tender-offer-purchase-16-million-common-stock\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3357950\" data-linked=\"Mannatech tenders for shares; stock jumps 24%\" data-tweet=\"$MTEX - Mannatech tenders for shares; stock jumps 24% https://seekingalpha.com/news/3357950-mannatech-tenders-for-shares-stock-jumps-24?source=tweet\" data-url=\"https://seekingalpha.com/news/3357950-mannatech-tenders-for-shares-stock-jumps-24\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357943\" data-ts=\"1526651531\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMAT\" target=\"_blank\">AMAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357943-chip-stocks-slump-on-applied-materials-earnings-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chip stocks slump on Applied Materials earnings, guidance</a></h4><ul><li>        Applied Materials (<a href='https://seekingalpha.com/symbol/AMAT' title='Applied Materials, Inc.'>AMAT</a> <font color='red'>-9.3%</font>) earnings report and downside revenue guidance are tugging down chip stocks this morning.</li><li>               On the move: Lam Research (<a href='https://seekingalpha.com/symbol/LRCX' title='Lam Research Corporation'>LRCX</a> <font color='red'>-4.5%</font>), Universal Display (<a href='https://seekingalpha.com/symbol/OLED' title='Universal Display Corporation'>OLED</a> <font color='red'>-4.9%</font>), KLA-Tencor (<a href='https://seekingalpha.com/symbol/KLAC' title='KLA-Tencor Corporation'>KLAC</a> <font color='red'>-3.7%</font>), Teradyne (<a href='https://seekingalpha.com/symbol/TER' title='Teradyne Inc.'>TER</a> <font color='red'>-1.9%</font>), Qorvo (<a href='https://seekingalpha.com/symbol/QRVO' title='Qorvo, Inc'>QRVO</a> <font color='red'>-1.4%</font>), Skyworks Solutions (<a href='https://seekingalpha.com/symbol/SWKS' title='Skyworks Solutions, Inc.'>SWKS</a> <font color='red'>-1%</font>), FormFactor (<a href='https://seekingalpha.com/symbol/FORM' title='FormFactor, Inc.'>FORM</a> <font color='red'>-2.3%</font>), Micron (<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a> <font color='red'>-0.9%</font>), Intel (<a href='https://seekingalpha.com/symbol/INTC' title='Intel Corporation'>INTC</a> <font color='red'>-1.1%</font>), Amkor Technology (<a href='https://seekingalpha.com/symbol/AMKR' title='Amkor Technology, Inc.'>AMKR</a> <font color='red'>-2.4%</font>).&nbsp;</li><li>Semiconductor ETFs: <a href='https://seekingalpha.com/symbol/SOXL' title='Direxion Daily Semiconductor 3x Bull Shares ETF'>SOXL</a>, <a href='https://seekingalpha.com/symbol/SOXX' title='iShares PHLX SOX Semiconductor Sector Index ETF'>SOXX</a>, <a href='https://seekingalpha.com/symbol/SMH' title='VanEck Vectors Semiconductor ETF'>SMH</a>, <a href='https://seekingalpha.com/symbol/USD' title='ProShares Ultra Semiconductors ETF'>USD</a>, <a href='https://seekingalpha.com/symbol/PSI' title='Invesco Dynamic Semiconductors Portfolio ETF'>PSI</a>, <a href='https://seekingalpha.com/symbol/XSD' title='SPDR S&P Semiconductor ETF'>XSD</a>, <a href='https://seekingalpha.com/symbol/SOXS' title='Direxion Daily Semiconductor 3x Bear Shares ETF'>SOXS</a>, <a href='https://seekingalpha.com/symbol/SSG' title='ProShares UltraShort Semiconductors ETF'>SSG</a>, <a href='https://seekingalpha.com/symbol/FTXL' title='First Trust Nasdaq Semiconductor ETF'>FTXL</a>, <a href='https://seekingalpha.com/symbol/XTH' title='SPDR S&P Technology Hardware ETF'>XTH</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3357943\" data-linked=\"Chip stocks slump on Applied Materials earnings, guidance\" data-tweet=\"$AMAT $AMAT $LRCX - Chip stocks slump on Applied Materials earnings, guidance https://seekingalpha.com/news/3357943-chip-stocks-slump-on-applied-materials-earnings-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3357943-chip-stocks-slump-on-applied-materials-earnings-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>74&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357934\" data-ts=\"1526650950\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OPK\" target=\"_blank\">OPK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357934-opko-facing-proposed-non-coverage-of-4kscore-medicare-shares-down-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OPKO facing proposed non-coverage of 4Kscore by Medicare; shares down 4%</a></h4><ul><li>OPKO Health (<a href='https://seekingalpha.com/symbol/OPK' title='OPKO Health, Inc.'>OPK</a> <font color='red'>-3.5%</font>) slips on light volume out the gate this morning on the heels of a <a href=\"https://seekingalpha.com/pr/17168176-opko-plans-address-draft-local-coverage-determination-published-novitas-solutions-4kscore\" target=\"_blank\">draft policy</a> by Medicare administrative services provider Novitas Solutions denying coverage for its 4Kscore test.</li><li>The company intends to submit comments during the public comment period ending July 5.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3339860-long-term-study-results-support-value-opkos-4kscore-prostate-cancer-test\" target=\"_blank\">Long-term study results support value of OPKO's 4Kscore prostate cancer test</a> (March 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3357934\" data-linked=\"OPKO facing proposed non-coverage of 4Kscore by Medicare; shares down 4%\" data-tweet=\"$OPK - OPKO facing proposed non-coverage of 4Kscore by Medicare; shares down 4% https://seekingalpha.com/news/3357934-opko-facing-proposed-non-coverage-of-4kscore-medicare-shares-down-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3357934-opko-facing-proposed-non-coverage-of-4kscore-medicare-shares-down-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>44&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357933\" data-ts=\"1526650732\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GLCNF\" target=\"_blank\">GLCNF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357933-bloomberg-glencore-may-face-u-k-bribery-probe-over-congo-dealings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bloomberg: Glencore may face U.K. bribery probe over Congo dealings</a></h4><ul><li>Glencore (<a href='https://seekingalpha.com/symbol/GLCNF' title='Glencore Plc'>OTCPK:GLCNF</a>, <a href='https://seekingalpha.com/symbol/GLNCY' title='Glencore Plc ADR'>OTCPK:GLNCY</a>) <font color='red'>-6.8%</font> in London trading, its worst decline in nearly two years, following a report that it <a href=\"https://www.ft.com/content/43d40aec-5a98-11e8-bdb7-f6677d2e1ce8\" target=\"_blank\">may face a bribery probe</a> by the U.K.&rsquo;s Serious Fraud Office over its ties to Israeli billionaire Dan Gertler in the Democratic Republic of Congo.</li><li>The SFO is planning to seek formal approval for a probe into Glencore&rsquo;s  dealings in DRC with its former business partner,  according to a Bloomberg report.</li><li>Gertler was sanctioned by the U.S. last year for his &ldquo;opaque and corrupt mining and oil deals&rdquo; in DRC; he owned stakes in Glencore&rsquo;s two key projects in the country before Glencore bought him out for $960M in 2017.</li></ul><div class=\"tiny-share-widget\" data-id=\"3357933\" data-linked=\"Bloomberg: Glencore may face U.K. bribery probe over Congo dealings\" data-tweet=\"$GLCNF $GLCNF $GLNCY - Bloomberg: Glencore may face U.K. bribery probe over Congo dealings https://seekingalpha.com/news/3357933-bloomberg-glencore-may-face-u-k-bribery-probe-over-congo-dealings?source=tweet\" data-url=\"https://seekingalpha.com/news/3357933-bloomberg-glencore-may-face-u-k-bribery-probe-over-congo-dealings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357927\" data-ts=\"1526650106\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357927-neteaseminus-0_9-after-ccb-international-cuts-to-neutral\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NetEase -0.9% after CCB International cuts to Neutral</a></h4><ul>   <li>NetEase is set to add to post-earnings declines, <font color='red'>down 0.9%</font> premarket after a downgrade to Neutral at CCB International Securities.</li>    <li>The cut is from a previous Outperform rating; analyst Ronnie Ho lowered the price target on ADRs to $280 from $300, implying 14% upside.</li>    <li>The ADRs are <font color='red'>down 28.7%</font> so far in 2018, taking some edge off gains in November and December.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3357676-netease-minus-9_1-percent-miss-analyst-caution-costs\" target=\"_blank\">NetEase -9.1% after miss, analyst caution on costs</a> (May. 17 2018)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3357480-netease-minus-4_1-percent-forex-losses-spur-miss-earnings\" target=\"_blank\">NetEase -4.1% as forex losses spur miss on earnings</a> (May. 16 2018)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3357927\" data-linked=\"NetEase -0.9% after CCB International cuts to Neutral\" data-tweet=\"NetEase -0.9% after CCB International cuts to Neutral https://seekingalpha.com/news/3357927-neteaseminus-0_9-after-ccb-international-cuts-to-neutral?source=tweet\" data-url=\"https://seekingalpha.com/news/3357927-neteaseminus-0_9-after-ccb-international-cuts-to-neutral\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357926\" data-ts=\"1526650006\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VLRX\" target=\"_blank\">VLRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357926-premarket-gainers-of-9-05-5-18-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am (5/18/2018)</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/VLRX' title='Valeritas Holdings, Inc.'>VLRX</a>&nbsp;<font color='green'>+36%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3357884-two-studies-support-value-proposition-valeritas-v-go-insulin-delivery-device-shares-21\" target=\"_blank\">announcing</a> positive results across two new studies evaluating V-Go Insulin Delivery device.</li><li><a href='https://seekingalpha.com/symbol/TYHT' title='Shineco, Inc.'>TYHT</a>&nbsp;<font color='green'>+28%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3357791-shineco-reports-q3-results\" target=\"_blank\">Q3 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/SDR' title='SandRidge Mississippian Trust II'>SDR</a> <font color='green'>+7%</font>.</li><li><a href='https://seekingalpha.com/symbol/CERN' title='Cerner Corporation'>CERN</a>&nbsp;<font color='green'>+6%</font>&nbsp;on being <a href=\"https://seekingalpha.com/news/3357865-cerner-awarded-va-contract-new-ehr-system-valued-high-10b-10-years-shares-6-percent-premarket\" target=\"_blank\">awarded</a> VA contract for new EHR system.</li><li><a href='https://seekingalpha.com/symbol/SPHS' title='Sophiris Bio'>SPHS</a>&nbsp;<font color='green'>+6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3357908-premarket-analyst-action-healthcare\" target=\"_blank\">overweight</a> analyst rating.</li><li><a href='https://seekingalpha.com/symbol/AMRS' title='Amyris, Inc.'>AMRS</a> <font color='green'>+5%</font>&nbsp;on its JV company Novvi <a href=\"https://seekingalpha.com/pr/17168076-amyris-sustainable-lubricants-joint-venture-company-novvi-chevron-enter-agreement-develop\" target=\"_blank\">signing deal</a> with Chevron to develop and novel renewable base oil technologies.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3357926\" data-linked=\"Premarket Gainers as of 9:05 am (5/18/2018)\" data-tweet=\"$VLRX $VLRX $TYHT - Premarket Gainers as of 9:05 am (5/18/2018) https://seekingalpha.com/news/3357926-premarket-gainers-of-9-05-5-18-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3357926-premarket-gainers-of-9-05-5-18-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357923\" data-ts=\"1526649376\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YELP\" target=\"_blank\">YELP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357923-yelpplus-3_4-b-riley-boosts-to-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Yelp +3.4% as B. Riley boosts to Buy</a></h4><ul>   <li>Yelp (NYSE:<a href='https://seekingalpha.com/symbol/YELP' title='Yelp'>YELP</a>) is <font color='green'>up 3.4%</font> premarket after B. Riley FBR upgrades to Buy, looking toward the company's continued lockdown on restaurants along with a big opportunity in home services.</li>    <li>Acquisitions of TurnStyle and NoWait have helped Yelp maintain a hold on the restaurant category, which makes up 14% of revenue, analyst Sameet Sinha says. Meanwhile, Home Services is a \"highly fragmented $500B-plus market\" that makes up 32% of revenue and should see continued momentum. (h/t Bloomberg)</li>    <li>Riley raised its price target on the company to $58 from $42, implying 28% upside.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3357923\" data-linked=\"Yelp +3.4% as B. Riley boosts to Buy\" data-tweet=\"$YELP - Yelp +3.4% as B. Riley boosts to Buy https://seekingalpha.com/news/3357923-yelpplus-3_4-b-riley-boosts-to-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3357923-yelpplus-3_4-b-riley-boosts-to-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357921\" data-ts=\"1526649319\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARQL\" target=\"_blank\">ARQL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357921-premarket-losers-of-9-05-5-18-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am (5/18/2018)</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/ARQL' title='ArQule, Inc.'>ARQL</a>&nbsp;<font color='red'>-9%</font>&nbsp;after <a href=\"https://seekingalpha.com/news/3357807-arqule-minus-6_3-percent-registers-10_6m-shares-selling-holders\" target=\"_blank\">registering</a> 10.6M shares for sale by certain stockholders.</li><li><a href='https://seekingalpha.com/symbol/CPB' title='Campbell Soup Company'>CPB</a>&nbsp;<font color='red'>-8%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3357868-campbell-soup-beats-0_09-misses-revenue\" target=\"_blank\">Q3 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/TNTR-OLD' title='Tintri, Inc.'>TNTR-OLD</a> <font color='red'>-8%</font>.</li><li><a href='https://seekingalpha.com/symbol/CHKR' title='Chesapeake Granite Wash Trust'>CHKR</a> <font color='red'>-8%</font>.</li><li><a href='https://seekingalpha.com/symbol/JWN' title='Nordstrom Inc.'>JWN</a>&nbsp;<font color='red'>-8%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3357764-nordstrom-beats-0_07-beats-revenue\" target=\"_blank\">Q1 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/AMAT' title='Applied Materials, Inc.'>AMAT</a>&nbsp;<font color='red'>-6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3357761-applied-materials-beats-0_08-beats-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/INSY' title='Insys Therapeutics, Inc.'>INSY</a>&nbsp;<font color='red'>-6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3357919-insys-5-percent-premarket-ad-com-doc-release\" target=\"_blank\">Ad Com doc</a> release.</li><li><a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a> <font color='red'>-5%</font>.</li><li><a href='https://seekingalpha.com/symbol/BOOT' title='Boot Barn Holdings'>BOOT</a>&nbsp;<font color='red'>-5%</font>&nbsp;after <a href=\"https://seekingalpha.com/news/3357816-boot-barn-minus-3_6-percent-7_2m-share-offering-said-come-23_50-24\" target=\"_blank\">launching</a> a&nbsp;7.21M-share public offering&nbsp;for selling stockholders.</li><li><a href='https://seekingalpha.com/symbol/BIDU' title='Baidu, Inc.'>BIDU</a>&nbsp;<font color='red'>-5%</font>&nbsp;after Qi Lu&nbsp;<a href=\"https://seekingalpha.com/news/3357873-baidu-coo-will-step-shares-minus-6-percent\" target=\"_blank\">steps out</a> of COO role.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3357921\" data-linked=\"Premarket Losers as of 9:05 am (5/18/2018)\" data-tweet=\"$ARQL $ARQL $CPB - Premarket Losers as of 9:05 am (5/18/2018) https://seekingalpha.com/news/3357921-premarket-losers-of-9-05-5-18-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3357921-premarket-losers-of-9-05-5-18-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357919\" data-ts=\"1526648787\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INSY\" target=\"_blank\">INSY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357919-insys-down-5-premarket-on-ad-com-doc-release\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">INSYS down 5% premarket on Ad Com doc release</a></h4><ul><li>INSYS Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/INSY' title='Insys Therapeutics, Inc.'>INSY</a>) slips&nbsp;<font color='red'>5%</font>&nbsp;premarket on light volume on the heels of the release of briefing documents for next Tuesday's Ad Com review for Buvaya.</li><li>Per the FDA document (page 25): \"In conclusion, the Applicant&rsquo;s efficacy data demonstrate superiority of [Buvaya] over placebo for all doses tested, however time to onset of analgesia is later than is optimal for a drug intended to treat acute pain and the need for rescue analgesic was high. From a safety perspective, there is an unexpectedly high rate of nausea, vomiting and dizziness for [Buvaya]. And the Applicant showed in a comparative safety study that rates for [Buvaya] are markedly higher than rates for other opioids (morphine and oxycodone) used in similar acute pain settings. <strong>The totality of data submitted by the Applicant does not support the use of this product in an acute pain setting, based on both efficacy and safety findings</strong>.\"</li><li>Previously: <a href=\"https://seekingalpha.com/news/3357891-ad-com-review-next-week-insys-therapeutics-pain-med-buprenorphine-sublingual-spray\" target=\"_blank\">Ad Com review next week for INSYS Therapeutics' pain med buprenorphine sublingual spray</a> (May 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3357919\" data-linked=\"INSYS down 5% premarket on Ad Com doc release\" data-tweet=\"$INSY $INSYQ - INSYS down 5% premarket on Ad Com doc release https://seekingalpha.com/news/3357919-insys-down-5-premarket-on-ad-com-doc-release?source=tweet\" data-url=\"https://seekingalpha.com/news/3357919-insys-down-5-premarket-on-ad-com-doc-release\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357911\" data-ts=\"1526648446\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PERY\" target=\"_blank\">PERY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357911-feldenkreis-ramps-up-pressure-on-perry-ellis\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Feldenkreis ramps up pressure on Perry Ellis</a></h4><ul> <li>Perry Ellis International (<a href='https://seekingalpha.com/symbol/PERY' title='Perry Ellis International Inc.'>PERY</a> <font color='red'>-1.7%</font>) shareholder George Feldenkreis is keeping up the <a href=\"https://seekingalpha.com/pr/17168099-george-feldenkreis-nominates-four-highly-qualified-individuals-election-board-perry-ellis\" target=\"_blank\">pressure</a> on the company's board.</li><li>The investor wants negotiations over an acquisition to progress and has nominated Oscar Feldenkreis, Mary Ellen Kanoff, Scott LaPorta and Matthew McEvoy for election to the board.</li> <li>Feldenkreis holds a stake of 10.8% in Perry Ellis.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3357911\" data-linked=\"Feldenkreis ramps up pressure on Perry Ellis\" data-tweet=\"$PERY - Feldenkreis ramps up pressure on Perry Ellis https://seekingalpha.com/news/3357911-feldenkreis-ramps-up-pressure-on-perry-ellis?source=tweet\" data-url=\"https://seekingalpha.com/news/3357911-feldenkreis-ramps-up-pressure-on-perry-ellis\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357908\" data-ts=\"1526648277\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AIMT\" target=\"_blank\">AIMT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357908-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Aimmune Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AIMT' title='Aimmune Therapeutics'>AIMT</a>) initiated with Overweight rating and $60 (100% upside) price target at Piper Jaffray.</li><li>Nivalis (NASDAQ:<a href='https://seekingalpha.com/symbol/ALPN' title='Alpine Immune Sciences, Inc.'>ALPN</a>) initiated with Outperform rating and $13 (48% upside) price target at Wedbush.</li><li>Amneal Pharmaceuticals (NYSE:<a href='https://seekingalpha.com/symbol/AMRX' title='Amneal Pharmaceuticals, Inc.'>AMRX</a>) initiated with Neutral rating and $18 (7% upside) price target at JPMorgan.</li><li>Five Prime Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/FPRX' title='Five Prime Therapeutics, Inc.'>FPRX</a>) initiated with Neutral rating and $17 (10% downside risk) price target at Wedbush.</li><li>Adverum Biotechnologies (NASDAQ:<a href='https://seekingalpha.com/symbol/ADVM' title='Adverum Biotechnologies, Inc.'>ADVM</a>) resumed with Overweight rating and $12 (100% upside) price target at Piper.</li><li>Ovid Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/OVID' title='Ovid Therapeutics Inc.'>OVID</a>) resumed with Overweight rating and $20 (120% upside) price target at Piper.</li><li>Sophiris Bio (NASDAQ:<a href='https://seekingalpha.com/symbol/SPHS' title='Sophiris Bio'>SPHS</a>) resumed with Overweight rating and $7 (108% upside) price target at Piper. Shares are up&nbsp;<font color='green'>7%</font>&nbsp;premarket on average volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3357908\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$AIMT $AIMT $ALPN - Premarket analyst action - healthcare https://seekingalpha.com/news/3357908-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3357908-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357903\" data-ts=\"1526647393\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GOOG\" target=\"_blank\">GOOG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357903-alphabetminus-1_5-ahead-of-critical-60-minutes-episode\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alphabet -1.5% ahead of critical &quot;60 Minutes&quot; episode</a></h4><ul><li>Alphabet (NASDAQ:<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet, Inc. Cl C'>GOOG</a>) shares&nbsp;<font color='red'>slip 1.5%</font>&nbsp;premarket due to a planned &ldquo;60 Minutes&rdquo; story that will air Sunday.</li><li>The show will feature critics who claim Alphabet has stifled competition and an antitrust enforcer fighting Alphabet&rsquo;s actions.</li><li>Source: <a href=\"https://www.cbsnews.com/video/the-power-of-google/\" target=\"_blank\">CBS News</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3335268-google-rivals-go-eu-antitrust-regulator-google-talks-startup-housing\" target=\"_blank\">Google rivals go to EU antitrust regulator; Google talks to startup about housing</a> (Feb. 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3357903\" data-linked=\"Alphabet -1.5% ahead of critical &quot;60 Minutes&quot; episode\" data-tweet=\"$GOOG - Alphabet -1.5% ahead of critical &quot;60 Minutes&quot; episode https://seekingalpha.com/news/3357903-alphabetminus-1_5-ahead-of-critical-60-minutes-episode?source=tweet\" data-url=\"https://seekingalpha.com/news/3357903-alphabetminus-1_5-ahead-of-critical-60-minutes-episode\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>76&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357902\" data-ts=\"1526647353\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMGN\" target=\"_blank\">AMGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357902-amgens-first-mover-advantage-aimovig-bodes-well-analysts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amgen&#39;s first mover advantage with Aimovig bodes well - analysts</a></h4><ul><li>As expected, sell-side analysts are bullish on Amgen (NASDAQ:<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a>) after getting the FDA nod on migraine med Aimovig (erenumab-aooe), the first CGRP inhibitor approved in the U.S.</li><li>Leerink's Geoffrey Porges (Market Perform/$210): sees 20% upside in the stock considering \"sensible price\" and \"clean label.\"</li><li>Jefferies' Michael Yee (Buy/$200): price was \"lower than expected\" and \"sends a good message.\" Price may fall to the $5K - 6K range which would align with Allergan's (NYSE:<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a>) Botox at ~$6K.</li><li>Mizuho's Salim Syed (Buy/$200): label \"super clean\" but questions the company's math considering the price.</li><li>Amgen expects to generate $81M in Aimovig sales this year, reaching over $1B by 2024.</li><li>FDA decision on Eli Lilly's (NYSE:<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a>) CGRP inhibitor galcanezumab expected in Q3.</li><li>Source: Bloomberg</li><li>Related tickers: (NASDAQ:<a href='https://seekingalpha.com/symbol/ALDR' title='Alder Biopharmaceuticals Inc.'>ALDR</a>) (NYSE:<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a>) (NYSE:<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a>)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3357862-fda-oks-amgen-novartis-migraine-med-aimovig\" target=\"_blank\">FDA OKs Amgen and Novartis' migraine med Aimovig</a> (May 18)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3317578-fda-accepts-lillys-marketing-application-migraine-med-galcanezumab\" target=\"_blank\">FDA accepts Lilly's marketing application for migraine med galcanezumab</a> (Dec. 11, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3357902\" data-linked=\"Amgen&#39;s first mover advantage with Aimovig bodes well - analysts\" data-tweet=\"$AMGN $AMGN $AGN - Amgen&#39;s first mover advantage with Aimovig bodes well - analysts https://seekingalpha.com/news/3357902-amgens-first-mover-advantage-aimovig-bodes-well-analysts?source=tweet\" data-url=\"https://seekingalpha.com/news/3357902-amgens-first-mover-advantage-aimovig-bodes-well-analysts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357901\" data-ts=\"1526646911\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CEVA\" target=\"_blank\">CEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357901-cowen-semiconductor-initiation-roundup\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cowen semiconductor initiation roundup</a></h4><ul><li>        Cowen&rsquo;s initiation spree for semiconductors continues.</li><li>               Initiated at Outperform: Ceva (NASDAQ:<a href='https://seekingalpha.com/symbol/CEVA' title='CEVA, Inc.'>CEVA</a>), Broadcom (NASDAQ:<a href='https://seekingalpha.com/symbol/AVGO' title='Broadcom Limited'>AVGO</a>), DSP (NASDAQ:<a href='https://seekingalpha.com/symbol/DSPG' title='DSP Group, Inc.'>DSPG</a>), and Silicon Labs (NASDAQ:<a href='https://seekingalpha.com/symbol/SLAB' title='Silicon Laboratories, Inc.'>SLAB</a>).&nbsp;</li><li>               Initiated at Outperform: Intel (NASDAQ:<a href='https://seekingalpha.com/symbol/INTC' title='Intel Corporation'>INTC</a>), Qualcomm (NASDAQ:<a href='https://seekingalpha.com/symbol/QCOM' title='Qualcomm Inc.'>QCOM</a>), and Cirrus Logic (NASDAQ:<a href='https://seekingalpha.com/symbol/CRUS' title='Cirrus Logic, Inc.'>CRUS</a>).&nbsp;</li><li>               Source: Briefing.com.&nbsp;</li><li>                  Ceva shares are&nbsp;<font color='green'>up 0.8%</font>&nbsp;premarket to $33.50.    </li><li>               Intel shares are&nbsp;<font color='red'>down 0.3</font>% to $54.64.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3357897-cowen-initiates-monolithic-power-systems-16-percent-upside\" target=\"_blank\">Cowen initiates Monolithic Power Systems at 16% upside</a> (May 18)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3357885-cowen-initiates-amd-40-percent-upside-shares-plus-2_7-percent\" target=\"_blank\">Cowen initiates AMD at 40% upside; shares +2.7%</a> (May 18)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3357888-cowen-initiates-nvidia-31-percent-upside\" target=\"_blank\">Cowen initiates Nvidia at 31% upside</a> (May 18)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3357893-cowen-initiates-ambarella-31-percent-upside-shares-plus-1_7-percent\" target=\"_blank\">Cowen initiates Ambarella at 31% upside; shares +1.7%</a> (May 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3357901\" data-linked=\"Cowen semiconductor initiation roundup\" data-tweet=\"$CEVA $CEVA $AVGO - Cowen semiconductor initiation roundup https://seekingalpha.com/news/3357901-cowen-semiconductor-initiation-roundup?source=tweet\" data-url=\"https://seekingalpha.com/news/3357901-cowen-semiconductor-initiation-roundup\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357897\" data-ts=\"1526646412\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MPWR\" target=\"_blank\">MPWR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357897-cowen-initiates-monolithic-power-systems-16-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cowen initiates Monolithic Power Systems at 16% upside</a></h4><ul><li>        Cowen <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/18/05/11738465/cowen-names-4-top-semi-picks-amd-ambarella-broadcom-mon\" target=\"_blank\">initiates</a> Monolithic Power Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/MPWR' title='Monolithic Power Systems, Inc.'>MPWR</a>) at Outperform with a $150 price target, a 16% upside to yesterday&rsquo;s close.</li><li>               Analyst Matthew Ramsay thinks that Monolithic Power Systems &ldquo;represents one of the most attractive organic growth stories in the semiconductor industry&rdquo; and notes that upcoming product ramps will help the company maintain a 21% growth rate. &nbsp;&nbsp;</li><li>               Monolithic Power Systems shares are&nbsp;<font color='green'>up 0.4%</font>&nbsp;premarket to $129.30.&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3357897\" data-linked=\"Cowen initiates Monolithic Power Systems at 16% upside\" data-tweet=\"$MPWR - Cowen initiates Monolithic Power Systems at 16% upside https://seekingalpha.com/news/3357897-cowen-initiates-monolithic-power-systems-16-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3357897-cowen-initiates-monolithic-power-systems-16-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357893\" data-ts=\"1526645836\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMBA\" target=\"_blank\">AMBA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357893-cowen-initiates-ambarella-31-upside-sharesplus-1_7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cowen initiates Ambarella at 31% upside; shares +1.7%</a></h4><ul><li>        Cowen <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/18/05/11738465/cowen-names-4-top-semi-picks-amd-ambarella-broadcom-mon\" target=\"_blank\">initiates</a> Ambarella (NASDAQ:<a href='https://seekingalpha.com/symbol/AMBA' title='Ambarella'>AMBA</a>) at Outperform with a $65 price target, a 31% upside to yesterday&rsquo;s close.</li><li>               Analyst Matthew Ramsay says Ambarella&rsquo;s near-term is challenging with the transition away from drone cameras but thinks investors are underestimating the long-term strategy.&nbsp;</li><li>               Ramsay cites new hardware release, the detailed computer vision plan, and a successful self-driving car demonstration using Ambarella technology as causes for confidence in the company&rsquo;s IP.&nbsp;</li><li>               Ambarella shares are&nbsp;<font color='green'>up 1.7%</font>&nbsp;premarket to $50.50. &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3357893\" data-linked=\"Cowen initiates Ambarella at 31% upside; shares +1.7%\" data-tweet=\"$AMBA - Cowen initiates Ambarella at 31% upside; shares +1.7% https://seekingalpha.com/news/3357893-cowen-initiates-ambarella-31-upside-sharesplus-1_7?source=tweet\" data-url=\"https://seekingalpha.com/news/3357893-cowen-initiates-ambarella-31-upside-sharesplus-1_7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357892\" data-ts=\"1526645808\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MAT\" target=\"_blank\">MAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357892-mattel-higher-mga-sniffing-around\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mattel higher with MGA sniffing around</a></h4><ul> <li>Mattel (NASDAQ:<a href='https://seekingalpha.com/symbol/MAT' title='Mattel, Inc.'>MAT</a>) rejected an <a href=\"https://www.wsj.com/articles/bratz-boss-makes-play-to-run-mattel-is-told-to-take-his-toys-and-go-home-1526637602\" target=\"_blank\">offer</a> from MGA Entertainment without getting far enough into deal discussions to talk about a price, according to MGA CEO Isaas Larian.</li> <li>MGA made the approach near the end of April.</li> <li>Larian indicated to the <em>WSJ</em> that he may take an offer directly to Mattel shareholders.</li> <li>Shares of Mattel are <font color='green'>up 3.08%</font> in premarket trading to $15.75.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3357892\" data-linked=\"Mattel higher with MGA sniffing around\" data-tweet=\"$MAT - Mattel higher with MGA sniffing around https://seekingalpha.com/news/3357892-mattel-higher-mga-sniffing-around?source=tweet\" data-url=\"https://seekingalpha.com/news/3357892-mattel-higher-mga-sniffing-around\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357888\" data-ts=\"1526644989\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVDA\" target=\"_blank\">NVDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357888-cowen-initiates-nvidia-31-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cowen initiates Nvidia at 31% upside</a></h4><ul><li>        Cowen <a href=\"https://www.cnbc.com/2018/05/18/amd-nvidia-shares-to-soar-on-autonomous-driving-cloud-chips-cowen.html\" target=\"_blank\">initiates</a> Nvidia (NASDAQ:<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a>) with an Outperform rating and a $325 price target, a 31% upside to yesterday&rsquo;s close.</li><li>               Analyst Matthew Ramsay expects Nvidia to dominate the self-driving vehicle and AI markets.&nbsp;</li><li>               Ramsay: &ldquo;In our view, no silicon company has the breadth of solutions and partnerships that NVIDIA has accumulated for end-to-end autonomous driving solutions.&rdquo;&nbsp;</li><li>               Nvidia shares are&nbsp;<font color='green'>up 0.9%</font>&nbsp;premarket to $249.90.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3357888\" data-linked=\"Cowen initiates Nvidia at 31% upside\" data-tweet=\"$NVDA - Cowen initiates Nvidia at 31% upside https://seekingalpha.com/news/3357888-cowen-initiates-nvidia-31-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3357888-cowen-initiates-nvidia-31-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>56&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357885\" data-ts=\"1526644630\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMD\" target=\"_blank\">AMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357885-cowen-initiates-amd-40-upside-sharesplus-2_7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cowen initiates AMD at 40% upside; shares +2.7%</a></h4><ul><li>Cowen <a href=\"https://www.cnbc.com/2018/05/18/amd-nvidia-shares-to-soar-on-autonomous-driving-cloud-chips-cowen.html\" target=\"_blank\">starts</a> Advanced Micro Devices (NASDAQ:<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a>) at Outperform with an $18 price target, a 40% upside to yesterday&rsquo;s close.</li><li>Analyst Matthew Ramsay expects a 2H inflection of server sales &ldquo;when OEM sales should complement cloud growth&rdquo; and says the firm is &ldquo;confident in the impressive roster of cloud and OEM engagements.&rdquo;</li><li>AMD shares are&nbsp;<font color='green'>up 2.7%</font>&nbsp;premarket to $13.17.</li></ul><div class=\"tiny-share-widget\" data-id=\"3357885\" data-linked=\"Cowen initiates AMD at 40% upside; shares +2.7%\" data-tweet=\"$AMD - Cowen initiates AMD at 40% upside; shares +2.7% https://seekingalpha.com/news/3357885-cowen-initiates-amd-40-upside-sharesplus-2_7?source=tweet\" data-url=\"https://seekingalpha.com/news/3357885-cowen-initiates-amd-40-upside-sharesplus-2_7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>81&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357884\" data-ts=\"1526644467\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VLRX\" target=\"_blank\">VLRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357884-two-studies-support-value-proposition-of-valeritas-v-go-insulin-delivery-device-shares-up-21\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Two studies support value proposition of Valeritas&#39; V-Go Insulin Delivery device; shares up 21% premarket</a></h4><ul><li>Nano cap Valeritas Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/VLRX' title='Valeritas Holdings, Inc.'>VLRX</a>) is up&nbsp;<font color='green'>21%</font>&nbsp;premarket on average volume on the heels of its <a href=\"https://seekingalpha.com/pr/17167961-valeritas-announces-positive-clinical-results-across-two-new-studies-evaluating-v-go-wearable\" target=\"_blank\">announcement </a>of results from two studies assessing its V-Go Wearable Insulin Delivery device. The results were presented at the American Association of Clinical Endocrinologists Annual Scientific and Clinical Congress in Boston.</li><li>In a three-month evaluation in 60 type 2 diabetics under care at Kaiser Permanente in Southern California, the use of V-Go improved glycemic control in patients who were uncontrolled with prior regimens. Specifically, 60% of the patients had A1C levels above 9% (target is a maximum of 7%) prior to using V-Go which dropped to 22% after three months' use. In addition, significant reductions in A1C&nbsp;(-1.3%) and total daily dose &#40;TDD&#41;&nbsp;of insulin (-24 Units/day) were observed (both statistically significant).</li><li>Results from a pilot study involving seven type 2 diabetics who were on stable doses of at least three insulin injections/day before switching to V-Go for ~five weeks showed a 35% increase in average time in range while TDD decreased 39%.</li><li>The FDA approved V-Go in December 2010.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3350210-valeritas-v-go-wearable-insulin-delivery-device-shows-treatment-benefit-type-2-diabetics-real\" target=\"_blank\">Valeritas' V-Go wearable insulin delivery device shows treatment benefit in type 2 diabetics in real-world study; shares up 8% premarket</a> (April 30)</li></ul><div class=\"tiny-share-widget\" data-id=\"3357884\" data-linked=\"Two studies support value proposition of Valeritas&#39; V-Go Insulin Delivery device; shares up 21% premarket\" data-tweet=\"$VLRX - Two studies support value proposition of Valeritas&#39; V-Go Insulin Delivery device; shares up 21% premarket https://seekingalpha.com/news/3357884-two-studies-support-value-proposition-of-valeritas-v-go-insulin-delivery-device-shares-up-21?source=tweet\" data-url=\"https://seekingalpha.com/news/3357884-two-studies-support-value-proposition-of-valeritas-v-go-insulin-delivery-device-shares-up-21\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:54 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357882\" data-ts=\"1526644050\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357882-apples-homepod-ranks-fourth-in-smart-speaker-market\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apple&#39;s HomePod ranks fourth in smart speaker market</a></h4><ul><li>        Apple&rsquo;s (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) HomePods only sold 600K units in their first quarter of release, according to <a href=\"https://www.fastcompany.com/40574652/apples-homepod-only-takes-fourth-place-in-smart-speaker-race?partner=feedburner&amp;utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+fastcompany%2Fheadlines+%28Fast+Company%29\" target=\"_blank\">Strategy Analytics data</a>.</li><li>               The performance gives HomePod a 6% smart speaker market share compared to Amazon&rsquo;s (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) 4M quarterly Echo sales and 43.6% share and Google&rsquo;s (<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet, Inc. Cl C'>GOOG</a>, <a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet, Inc. Cl A'>GOOGL</a>) 2.4M Home sales and 26.5% market share. Alibaba&rsquo;s (NYSE:<a href='https://seekingalpha.com/symbol/BABA' title='Alibaba Group Holding Limited'>BABA</a>) smart speaker came in third with 700K units and a 7.6% share.&nbsp;</li><li>               But HomePod wasn&rsquo;t in last place: Xiaomi (<a href='https://seekingalpha.com/symbol/XI' title='Xiaomi'>XI</a>) only sold 200K units in the quarter for a 2.4% market share.&nbsp;</li><li>               Apple shares are&nbsp;<font color='green'>up 0.2%</font>&nbsp;premarket to $187.30.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3357882\" data-linked=\"Apple&#39;s HomePod ranks fourth in smart speaker market\" data-tweet=\"$AAPL $AAPL $AMZN - Apple&#39;s HomePod ranks fourth in smart speaker market https://seekingalpha.com/news/3357882-apples-homepod-ranks-fourth-in-smart-speaker-market?source=tweet\" data-url=\"https://seekingalpha.com/news/3357882-apples-homepod-ranks-fourth-in-smart-speaker-market\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>141&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357874\" data-ts=\"1526642775\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CPB\" target=\"_blank\">CPB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357874-campbell-soup-lower-5-after-results-ceo-exit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Campbell Soup lower by 5% after results, CEO exit</a></h4><ul><li>Campbell Soup (NYSE:<a href='https://seekingalpha.com/symbol/CPB' title='Campbell Soup Company'>CPB</a>)&nbsp;reports net sales increased 15% in <a href=\"https://seekingalpha.com/pr/17167987-campbell-reports-third-quarter-results\" target=\"_blank\">Q3</a>, driven by a 14-point benefit from the recent acquisitions of Snyder&rsquo;s-Lance and Pacific Foods and a 1-point favorable impact from currency translation.</li><li>Total volume and mix +1% for the period.</li><li>Revenue by segments:&nbsp;Americas simple meals and beverages: $1.01B (+5%);&nbsp;Global biscuits and snacks: $862M&nbsp;(+35%);&nbsp;Campbell fresh: $251M&nbsp;(+1%).</li><li>Adjusted gross margin rate squeezed 390 bps to 32%, primarily driven by cost inflation and higher supply chain costs, as well as the dilutive impact of recent acquisitions and higher promotional spending.</li><li><b>FY2018 Guidance</b>: Net sales: +10% to +11%; Adjusted EBIT: -8% to -6%; Adjusted EPS: $2.85 to $2.90 (-6% to -5%).</li><li>CEO Denise Morrison <a href=\"https://seekingalpha.com/pr/17167984-campbell-soup-company-announces-ceo-transition-plan\" target=\"_blank\">is out effective today</a>, replaced on an interim basis by board member Keith McLoughlin.</li><li>CPB&nbsp;<font color='red'>-5%</font>&nbsp;premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3357874\" data-linked=\"Campbell Soup lower by 5% after results, CEO exit\" data-tweet=\"$CPB - Campbell Soup lower by 5% after results, CEO exit https://seekingalpha.com/news/3357874-campbell-soup-lower-5-after-results-ceo-exit?source=tweet\" data-url=\"https://seekingalpha.com/news/3357874-campbell-soup-lower-5-after-results-ceo-exit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357870\" data-ts=\"1526642526\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IQV\" target=\"_blank\">IQV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357870-iqvia-reaffirms-q2-and-fy-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IQVIA reaffirms Q2 and FY guidance</a></h4><ul> <li>IQVIA Holdings (NYSE:<a href='https://seekingalpha.com/symbol/IQV' title='IQVIA Holdings, Inc.'>IQV</a>) <a href=\"https://seekingalpha.com/pr/17167859-iqvia-reaffirms-second-quarter-full-year-2018-guidance-including-adjusted-eps-growth-13_6\" target=\"_blank\">reaffirms</a> its Q2 and       FY 2018 guidance previously provided on May 2.</li><li><strong>Q2 Guidance</strong>: Revenues: $2.47B - 2.52B; non-GAAP EPS: $1.17 - 1.24; non-GAAP EBITDA: $510M - 530M.</li><li><strong>2018 Guidance</strong>: Revenues: $10.05B - 10.25B; non-GAAP EPS: $5.20 - 5.45; non-GAAP EBITDA: $2.15B - 2.22B.</li><li>Shares are up&nbsp;<font color='green'>4%</font>&nbsp;premarket.</li>               </ul><div class=\"tiny-share-widget\" data-id=\"3357870\" data-linked=\"IQVIA reaffirms Q2 and FY guidance\" data-tweet=\"$IQV - IQVIA reaffirms Q2 and FY guidance https://seekingalpha.com/news/3357870-iqvia-reaffirms-q2-and-fy-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3357870-iqvia-reaffirms-q2-and-fy-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:22 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357867\" data-ts=\"1526642252\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IQV\" target=\"_blank\">IQV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357867-iqvia-holdings-provides-update-on-secondary-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IQVIA Holdings provides update on secondary offering</a></h4><ul> <li>IQVIA Holdings (NYSE:<a href='https://seekingalpha.com/symbol/IQV' title='IQVIA Holdings, Inc.'>IQV</a>) and selling stockholders <a href=\"https://seekingalpha.com/pr/17167850-iqvia-holdings-inc-provides-update-secondary-offering\" target=\"_blank\">terminate</a>&nbsp;the previously announced secondary public offering and repurchase due to the recent market conditions.</li><li>Shares are up&nbsp;<font color='green'>4%</font>&nbsp;premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3357167-iqvia-launches-secondary-offering-repurchase-common-stock\" target=\"_blank\">IQVIA launches secondary offering and repurchase of common stock</a> (May 16)</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3357867\" data-linked=\"IQVIA Holdings provides update on secondary offering\" data-tweet=\"$IQV - IQVIA Holdings provides update on secondary offering https://seekingalpha.com/news/3357867-iqvia-holdings-provides-update-on-secondary-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3357867-iqvia-holdings-provides-update-on-secondary-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357865\" data-ts=\"1526642049\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CERN\" target=\"_blank\">CERN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357865-cerner-awarded-va-contract-for-new-ehr-system-valued-high-10b-over-10-years-shares-up-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cerner awarded VA contract for new EHR system valued as high as $10B over 10 years; shares up 6% premarket</a></h4><ul><li>The Veterans Administration has awarded a <a href=\"https://www.va.gov/opa/pressrel/pressrelease.cfm?id=4061\" target=\"_blank\">contract </a>to Cerner (NASDAQ:<a href='https://seekingalpha.com/symbol/CERN' title='Cerner Corporation'>CERN</a>) to modernize its healthcare IT system aimed at providing seamless care to Veterans as they transition from military service to Veteran status and when they choose to use community care.</li><li>The electronic health record &#40;EHR&#41; contract is valued as high as $10B over 10 years. $782M is earmarked for fiscal 2018 to get the project underway.</li><li>CERN is up&nbsp;<font color='green'>6%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3357865\" data-linked=\"Cerner awarded VA contract for new EHR system valued as high as $10B over 10 years; shares up 6% premarket\" data-tweet=\"$CERN - Cerner awarded VA contract for new EHR system valued as high as $10B over 10 years; shares up 6% premarket https://seekingalpha.com/news/3357865-cerner-awarded-va-contract-for-new-ehr-system-valued-high-10b-over-10-years-shares-up-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3357865-cerner-awarded-va-contract-for-new-ehr-system-valued-high-10b-over-10-years-shares-up-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357862\" data-ts=\"1526641548\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMGN\" target=\"_blank\">AMGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357862-fda-oks-amgen-and-novartis-migraine-med-aimovig\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Amgen and Novartis&#39; migraine med Aimovig</a></h4><ul><li>Amgen (NASDAQ:<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a>) and collaboration partner Novartis (NYSE:<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a>) <a href=\"https://seekingalpha.com/pr/17167837-novartis-amgen-announce-fda-approval-aimovig-erenumab-aooe-novel-treatment-developed\" target=\"_blank\">announce </a>that the FDA has approved Aimovig (erenumab-aooe) for the prevention of migraine in adults.</li><li>The calcitonin gene-related peptide receptor (CGRP-R) blocker is a self-administered once/month via Amgen's SureClick autoinjector.</li><li>The U.S. price is $575 per 70 mg or 140 mg single-use autoinjector or $6,900 per year. Patient out-of-pocket costs could be as low as $5 per month depending on insurance coverage. Commercial availability should commence within one week.</li><li>Under their 2015 neuroscience collaboration, the companies will co-promote Aimovig in the U.S. while Amgen owns exclusive rights in Japan and Novartis the rest of the world.</li><li>Novartis' marketing application in Europe is currently under review with a decision expected in the coming months.</li><li>AMGN is up&nbsp;<font color='green'>1%</font>&nbsp;and NVS a fraction premarket, both on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3357862\" data-linked=\"FDA OKs Amgen and Novartis&#39; migraine med Aimovig\" data-tweet=\"$AMGN $AMGN $NVS - FDA OKs Amgen and Novartis&#39; migraine med Aimovig https://seekingalpha.com/news/3357862-fda-oks-amgen-and-novartis-migraine-med-aimovig?source=tweet\" data-url=\"https://seekingalpha.com/news/3357862-fda-oks-amgen-and-novartis-migraine-med-aimovig\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3357853\" data-ts=\"1526638818\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZN\" target=\"_blank\">AZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3357853-astrazeneca-q1-revenues-down-4-shares-off-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AstraZeneca Q1 revenues down 4%; shares off 2% premarket</a></h4><ul><li>AstraZeneca (<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a>) <a href=\"https://www.astrazeneca.com/content/dam/az/PDF/2018/Q1-2018/Q1%202018%20Results%20announcement.pdf\" target=\"_blank\">Q1 results</a>: Revenues: $5,178M (-4.2%); Product Sales: $4985M (2.9%); Externalisation Revenue: $193M (-65.7%).</li><li>Net Income: $316M (-38.3%); EPS: $0.27 (-35.7%); Non-GAAP EPS: $0.48; Quick Assets: $3,005M (-9.6%); CF Ops: $105M (-69.0%).</li><li><strong>2018 Guidance</strong>: Product Sales: A low single-digit percentage increase (unch); Core EPS: $3.30 - 3.50 (unch).</li><li>Shares are down&nbsp;<font color='red'>2%</font>&nbsp;premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3357853\" data-linked=\"AstraZeneca Q1 revenues down 4%; shares off 2% premarket\" data-tweet=\"$AZN - AstraZeneca Q1 revenues down 4%; shares off 2% premarket https://seekingalpha.com/news/3357853-astrazeneca-q1-revenues-down-4-shares-off-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3357853-astrazeneca-q1-revenues-down-4-shares-off-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":66,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}